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ABSTRACT 
THORFINN RIDAY: Cortical experience-dependent plasticity and mesostriatal 
dopaminergic dysfunction in a mouse model of Angelman syndrome  
(Under the direction of Bejamin Philpot) 
 
Sensory experience guides development of neocortical circuits.  This activity-
dependent circuit maturation is required for normal sensory and cognitive abilities, which are 
distorted in neurodevelopmental disorders.  Here we have tested whether experience-
dependent cortical modifications require Ube3a, an E3 ubiquitin ligase whose dysregulation 
has been implicated in both autism and Angelman syndrome (AS).  Using the visual cortex as 
a model system for neocortical plasticity, we found that the genetic deletion of UBE3A 
attenuates activity-dependent synaptic strengthening and weakening in visual cortical slices.  
Chronic recordings of visual evoked potentials (VEPs) from awake mice also exhibited 
deficits in critical period ocular dominance plasticity, an in vivo assay for experience-
dependent synaptic weakening.  Stimulus-specific response potentiation (SRP) of VEPs was 
used as an assay of experience-dependent synaptic strengthening.  Contrary to the results 
observed in in vitro slice preparations, we observed developmentally enhanced potentiation 
of VEPs, including increased power of spontaneous local field potentials (LFP) in AS mice.  
WT and AS mice achieved similar increases in VEP amplitude with a longer period of visual 
stimulation, indicating the threshold for potentiation was lower in AS mice.  Augmented 
plasticity and increased spontaneous LFP power were absent from mice maternally 
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expressing Ube3a in inhibitory neurons alone.  Our results suggest that sensory experience-
dependent cortical potentiation is enhanced in adult AS mice due to reduced inhibition.  
Previous studies also suggest that abnormal dopamine neurotransmission may 
underlie some of the motor deficits exhibited in AS. A clinical trial of levodopa (L-DOPA) in 
AS is ongoing, although the underlying rationale for this treatment strategy has not yet been 
thoroughly examined in preclinical models. We found that AS mice exhibited behavioral 
deficits that correlated with abnormal dopamine signaling. These deficits were not due to loss 
of dopaminergic neurons or impaired dopamine synthesis. Unexpectedly, AS mice exhibited 
increased dopamine release in the mesolimbic pathway while also exhibiting a decrease in 
dopamine release in the nigrostriatal pathway, as measured with fast-scan cyclic 
voltammetry. These findings demonstrate the complex effects of UBE3A loss on dopamine 
signaling in subcortical motor pathways that may inform ongoing clinical trials of L-DOPA 
therapy in patients with AS. 
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CHAPTER 1 
1. Introduction 
 
1.1. Angelman Syndrome 
Angelman syndrome (AS) is an autism spectrum disorder occurring in 1 in 12,000 to 
20,000 births, characterized by profound mental retardation, lack of language, abnormal EEG 
activity, seizures, disrupted sleep patterns, puppet-like ataxic movements, inappropriate 
paroxysms of laughter, and hyperactivity (Steffenburg et al., 1996; Kishino et al., 1997a; 
Peters et al., 2004; Williams et al., 2006; Yashiro et al., 2009) (Table 1-1).  AS is caused by 
the functional loss of the Ube3a gene, found within the 15q11-q13 chromosomal locus, and is 
maternally imprinted in the brain.  The Ube3a gene encodes a HECT domain E3 ubiquitin 
ligase involved in protein degradation through the ubiquitin-associated proteosome pathway 
(Kishino et al., 1997b; Sutcliffe et al., 1997b).  The UBE3A gene encodes for three protein 
isoforms generated by differential splicing, however it is not known whether they differ in 
function or substrate specificity (Yamamoto et al., 1997).  Characterization of the 
endogenous properties and function of Ube3a, and its roles in the pathogenesis of Angelman 
syndrome, are essential in developing behavioral and pharmacological therapeutics. 
1.2. Causes of Angelman Syndrome 
The 15q11-13 chromosomal region is a relatively unstable region in which deletions, 
mutations, and imprinting defects can result is AS.  AS is most commonly (65-75%) caused 
by de novo deletions (5-7 Mb) to 15q11-q13 (Williams et al., 2010).  3-7% of individuals 
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with AS occur when two copies of the paternal chromosomal segment containing UBE3A are 
inherited (uniparental disomy), with the absence of a maternal copy. Another ~3% of 
individuals with AS exhibit normal biparental inheritance of the UBE3A allele, but do not 
express Ube3a because of an imprinting defect.  Defects in imprinting can occur as a result 
of abnormal DNA methylation patterns or small deletions in the imprinting center along 
15q11-q13, which regulates DNA methylation and imprinting in this region of genes.  5-11% 
of cases result from mutations in the UBE3A allele, indicating that loss of maternal Ube3a 
function alone is sufficient for AS. It is interesting to note that while loss of Ube3a function 
is sufficient for AS, the most commonly associated genetic variation with autism is 
duplication and triplication of the maternal 15q11-q13 locus containing UBE3A gene 
(Browne et al., 1997; Mao et al., 2000; Abrahams and Geschwind, 2008; Smith et al., 2011).   
1.3. Ube3a substrates and protein interactions 
Since the initial identification of Ube3a, a growing number of proteins have been shown 
to interact with Ube3a including p53 (Huibregtse et al., 1991), the human homologue A of 
Rad23 (Kumar et al., 1999), multicopy maintenance protein 7 (Kuhne and Banks, 1998), Src 
family kinase Blk (Oda et al., 1999), cyclin dependent kinase inhibitor p27 (Mishra et al., 
2009), immediate early gene Arc/Arg3.1 (Greer et al., 2010), RhoA guanine nucleotide 
exchange factor Ephexin5 (Margolis et al., 2010), and even Ube3a itself (Nuber et al., 1998) 
(Table 1-2).  However, the physiological relevance of many of these potential substrates is 
unknown, and may not all be germane to the body of symptoms encompassed by Angelman 
syndrome.   
Several of these substrates are involved in learning and memory, and may contribute to 
the cognitive disabilities in AS.  The neuronal activity-dependent gene Arc is required for 
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learning, long-term memory, and homeostatic plasticity (Mabb et al., 2011).  Absence of 
Ube3a increases Arc expression, dysregulating cell surface expression of AMPA receptors by 
increased endocytosis (Greer et al., 2010), a process thought to be critical in LTP and LTD 
(Bramham et al., 2008).   Ephexin5 interacts with EphrinB upon stimulation by EphB2, 
leading to activation of RhoA and the suppression of synapse and spine number.  
Degradation of Ephexin5 is mediated by Ube3a,  suggesting that the reduction in spine 
density observed in AS may be in part attributed to elevated Ephexin5 levels (Margolis et al., 
2010; Mabb et al., 2011).  Loss of Ube3a increases p27 levels in the cortex, hippocampus and 
cerebellum (Mishra et al., 2009).  It is known that increased p27 in the cortex promotes 
neuronal differentiation and migration (Nguyen et al., 2006), and therefore may alter cortical 
cytoarchitecture and function in AS. 
Another prominent feature of AS is motor dysfunction and at least two of the identified 
substrates appear to be involved.  There is evidence that Ube3a deficiency reduces 
degradation of GABA transporter 1 (GAT1).  The increase in GAT1 expression leads to 
lower ambient concentrations of extracellular GABA, which in turn decreases GABAA 
receptor-mediated tonic inhibition in cerebellar granule and purkinje cells (Egawa et al., 
2012).  The attenuated tonic inhibition in the cerebellum contributes to the ataxic-motor 
dysfunction in AS.  In addition to motor dysfunction attributed to the cerebellum, the Ube3a 
substrate α-synuclein (Mishra et al., 2009) implicates the nigrolstriatal pathway as well in 
AS.  α-Synuclein accumulates in protein inclusions called Lewy bodies, one of the 
pathophysiological hallmarks of the Parkinson’s disease (Kirik et al., 2002).  This 
neurodegenerative disorder results in dopaminergic cell loss in the substantia nigra (SNc).  
SNc dopaminergic cell loss has been documented in adult AS model mice, in conjunction 
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with nigrolstriatal-sensitive motor deficits (Mulherkar and Jana, 2010).  Parkinsonian 
symptoms like resting tremor, cogwheel rigidity and bradykinesia have been reported in 
adults with AS, and were responsive to dopamine replacement therapy (Harbord, 2001). 
1.4. Animal models of Angelman Syndrome 
Mouse models have contributed to the bulk of the neurological knowledge underlying 
the phenotypes of AS.  The earliest AS mouse model was created by parental duplication 
(partial parental disomy) of the homologous chromosomal region for 15q11-q13, where the 
UBE3A gene is located (Cattanach et al., 1997). These mice had several characteristics 
features of AS, including diffuse cortical slow-wave EEG abnormalities, cortical thinning 
and reduced brain weight, abnormal body weight growth curve, juvenile hyperactivity, and 
mild ataxia.  Employing in situ hybridization, evidence of maternal-specific expression of 
UBE3A in the mouse brain was demonstrated for the first time (Albrecht et al., 1997). 
After establishing UBE3A as the critical gene precipitating in AS (Kishino et al., 1997a), 
a mouse model was created that specifically targeted the sequence orthologous to human 
exon 2 of UBE3A via 3kb deletion, rendering the protein product inactive (Jiang et al., 
1998).  These maternally-deficient heterozygous Ube3a (Ube3am-/p+) mice have become the 
principle mouse model for AS research.  Similar to the parental disomy AS model, Ube3am-
/p+ mice also exhibited ataxia, reduced brain weight and abnormal EEG patterns, including 
audiogenic-induced seizures.  Learning and memory deficits were also observed in the 
context-dependent fear-conditioning paradigm, consistent with a reduction in hippocampal 
long-term potentiation (LTP).   
A subsequent study found that inhibitory phosphorylation at Thr305 of 
calcium/calmodulin-dependent protein kinase II (CaMKII) in the hippocampus was 
5 
 
increased, reducing the CaMKII activity (Weeber et al., 2003).  The dysregulation of 
CaMKII was discovered without changes in any other learning-related kinases.  This led to 
the hypothesis that dysregulation of CaMKII was responsible for the reduction in 
hippocampal LTP, which is dependent on CaMKII activation. A genetic rescue was 
performed by crossing Ube3am-/p+ mice with CaMKIIT305/T 306V mice, which were deficient in 
inhibitory CaMKII autophosphorylation (van Woerden et al., 2007).  The consequent 
offspring had comparable levels of CaMKII with wild-type mice.  Normal LTP-induction 
was reinstated, as well as rescuing their performance in a number of behavioral learning 
paradigms including context-dependent fear-conditioning, Morris water maze tasks, time on 
the rotarod.  
As in humans with AS, the observed motor deficits in the Ube3am-/p+ mice have been 
mostly ascribed to cerebellar dysfunction (Jiang et al., 1998; Cheron et al., 2005; Lalande and 
Calciano, 2007; Heck et al., 2008; Egawa et al., 2012).  In addition to deficits on the rotarod 
task, Ube3am-/p+ mice also exhibited deficits in rope climbing, grip strength, gait, balance on 
the raised-beam task, and increased licking behavior (Heck et al., 2008).  Although most of 
the studies of Ube3am-/p+ mice have attributed all the observed motor deficits to dysfunction 
of the Purkinje cells in the cerebellum, this has never been rigorously tested. Motor function 
is also regulated by the spinal cord and basal ganglia.  One study of the Ube3am-/p+ mice 
observed abnormalities in the nigrostriatal pathway.  In this report it was found that the 
number of dopamine cells in the SNc were significantly reduced in Ube3am-/p+ mice, and 
credited that loss for the poor performance on more nigralstriatial sensitive behavioral 
paradigms such as the raised balance beam and pole test (Mulherkar and Jana, 2010). 
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A second AS mouse model was generated that targeted the human orthologs to exon 15 
and 16 of the UBE3A gene (Miura et al., 2002).  As with the previous AS mouse model of 
Jiang et al. (1998), there were deficits in hippocampal-dependent memory tasks, LTP-
induction (and impaired neurogenesis), motor coordination, and increased occurrences of 
seizures (Miura et al., 2002; Mardirossian et al., 2009).  EEG recordings revealed abnormal 
wake/sleep patterns, including reduced time spent in rapid-eye movement (REM), as has 
been reported in many children with AS (Bruni et al., 2004; Miano et al., 2004; Colas et al., 
2005).  Electrophysiological recordings from the cerebellum exhibited fast oscillations 
sustained by increased Purkinje cell firing and rhythmicity (Cheron et al., 2005), as well as a 
reduction in tonic inhibition mediated by increased GAT1 expression and decreased 
extracellular levels of GABA (Cheron et al., 2005; Egawa et al., 2012).  Treatment with a 
GABAA agonist both increased tonic inhibition and reduced cell firing and rhythmicity, 
resulting in improved performance on the rotarod (Cheron et al., 2005); Egawa et al., 2012). 
Although targeted inactivation of maternal UBE3A by itself has been sufficient to cause 
characteristic AS features in the mouse models of Jiang et al. (1998) and Miura et al. (2002), 
the predominant form of AS in humans is caused by large deletions to 15q11-13 that also 
disrupt neighboring genes (Williams et al., 2010).  Clinical features of individuals with 
deletions to 15q11-13 are typically more severe than those with mutations, especially in 
regards to epilepsy (Smith et al., 1997; Minassian et al., 1998; Moncla et al., 1999; Lossie et 
al., 2001; Clayton-Smith and Laan, 2003; Mabb et al., 2011).  The increased incidence and 
severity of epilepsy may in part be due to disruptions in the neighboring GABRB3 gene, also 
known to cause epilepsy (DeLorey et al., 1998).  In order to better represent the large 
deletion class of AS, a mouse model was created with a maternal deletion that spanned 1.6 
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Mb, disrupting UBE3A, ATP10A, and GABRB3 (Jiang et al., 2010). This AS mouse model 
recapitulated many of the phenotypes of the two targeted UBE3A models, including impaired 
motor function and learning and memory deficits.  Future comparative studies of the large 
and micro deletion mouse models of AS will be informative in elucidating the contributing 
influence of ATP10A and GABRB3 to the severity of AS phenotypes, particularly epilepsy 
and the abnormal EEG patterns.    
An earlier AS mouse model with a transgene-induced mutation that generated a much 
larger 4 Mb deletion of the 15q11-13 region had been created many years ago (Gabriel et al., 
1999).  The deletion included UBE3A, ATP10A, GABRB3, GABRA5, GABRG3, P, 
HERC2, SNURF-SNRPN, NDN, ZFP127.  While imprinting of Ube3a was confirmed in the 
cerebellum, no behavioral characterization of the model was ever reported.  Another AS 
mouse model was created which disrupted the AS imprinting center (AS-IC) (Johnstone et 
al., 2006; Wu et al., 2006)Wu et al., 2006).  These models silenced Ube3a expression by 
disrupting the AS-IC, causing maternal Ube3a antisense transcription and the repression of 
Ube3a in cis (Johnstone et al., 2006; Wu et al., 2006).  Unfortunately, no behavioral 
descriptions of either AS-IC mouse models have been published to date.  
Interestingly, while loss of Ube3a expression results in AS, increased expression of 
Ube3a by duplication and triplication of the maternal UBE3A gene is linked to autism 
(Browne et al., 1997; Mao et al., 2000; Abrahams and Geschwind, 2008; Smith et al., 2011).  
To study how Ube3a overexpression relates to autism, mice that had two or three maternal 
copies of UBE3A were created (Smith et al., 2011).  As had been found in humans, 
penetrance of autistic traits such as reduced vocalizations (impaired communication), lack of 
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social preference (impaired social interactions) and increased grooming (stereotypy) were 
increased with UBE3A gene dosage.   
In addition to the many mouse models of AS, two drosophila models of also been 
created (Wu et al., 2008; Lu et al., 2009).  The drosophila homolog of UBE3A is dUBE3A, 
and when deleted resulted in impaired motor function, atypical climbing behavior and 
abnormal circadian rhythms (Wu et al., 2008).  The dUBE3A-deficient drosophila exhibited 
deficits in memory paradigms when training was spaced out, indicating a disruption in long-
term memory formation.  However, performance on massed training memory paradigms was 
normal, indicating intermediate-term memory was unaffected.  Morphology, dendritic 
branching was decreased, along with total dendritic length (Lu et al., 2009).  Overexpression 
of dUBE3A also reduced dendritic branching, suggesting a critical role of dUBE3A in 
regulating dendritic arborization.  
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Consistent (100%)  
Developmental delay, functionally severe 
Movement or balance disorder, usually ataxia of gait and/or tremulous movement of limbs. Movement 
disorder can be mild. May not appear as frank ataxia but can be forward lurching, unsteadiness, 
clumsiness, or quick, jerky motions 
Behavioral uniqueness: any combination of frequent laughter/smiling; apparent happy demeanor; easily 
excitable personality, often with uplifted hand-flapping or waving movements; hypermotoric behavior 
Speech impairment, none or minimal use of words; receptive and nonverbal communication skills higher 
than verbal ones 
Frequent (more than 80%) 
Delayed, disproportionate growth in head circumference, usually resulting in microcephaly (≤2 S.D. of 
normal OFC) by age 2 years. Microcephaly is more pronounced in those with 15q11.2-q13 deletions. 
Seizures, onset usually < 3 yrs. of age. Seizure severity usually decreases with age but the seizure disorder 
lasts throughout adulthood. 
Abnormal EEG, with a characteristic pattern, as mentioned in the text. The EEG abnormalities can occur 
in the first 2 years of life and can precede clinical features, and are often not correlated to clinical seizure 
events. 
Associated (20-80%) 
Flat occiput   
Occipital groove 
Protruding tongue 
Tongue thrusting; suck/swallowing disorders 
Feeding problems and/or truncal hypotonia during infancy 
Prognathia (overbite) 
Wide mouth, wide-spaced teeth 
Frequent drooling 
Excessive chewing/mouthing behaviors 
Strabismus 
Hypopigmented skin, light hair and eye color (compared to family), seen only in deletion cases 
Hyperactive lower extremity deep tendon reflexes 
Uplifted, flexed arm position especially during ambulation 
Wide based gait with pronated or valgus, positioned ankles 
Increased sensitivity to heat 
Abnormal sleep wake cycles and diminished need for sleep 
Attraction to/fascination with water; fascination with crinkly items such as certain papers and plastics 
Abnormal food related behaviors 
Obesity (in the older child) 
Scoliosis 
Constipation 
 
Table 1-1: Developmental and physical findings of Angelman Syndrome (from 2005 
consensus criterion document). This information is reprinted from Facts about Angelman 
syndrome (Charles A. Williams, 2009).  
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Protein Cellular function Reference 
Ube3a protein degradation (Nuber et al., 1998) 
P53 neural maturation, axon outgrowth and 
regeneration, neuronal apoptosis 
(Jiang et al., 1998) 
Multicopy maintenance  
protein 7 (MCM7) 
involved in initiation of DNA replication (Kuhne and Banks, 1998) 
Human homologue of 
Rad23A (HHR23A) 
DNA repair-enzyme Rad23 (Kumar et al., 1999) 
B-cell lymphocyte kinase 
(BLK) 
regulation of Src family kinases (Oda et al., 1999) 
Ubiquilin-1 and -2  
(UBQLN1 and -2) 
links ubiquitination machinery to the 
proteasome affecting protein degradation 
(Kleijnen et al., 2003),  
(Kleijnen et al., 2000) 
Estrogen receptor regulate gene transcription (Li et al., 2006a) 
Tuberous sclerosis protein 2 
(TSC2) 
negative regulator of mTor signaling pathway, 
neural migration 
(Zheng et al., 2008) 
α-synuclein involved in vesicle trafficking, 
neurodegenerative disorders  
(Mulherkar et al., 2009) 
Annexin A1  
(lipocortin I) 
anti-inflammation (protective for 
neurodegeneration) 
(Shimoji et al., 2009) 
Promyelocytic leukemia  
(PML) 
regulation of growth inhibition, senescence, 
apoptosis 
(Louria-Hayon et al., 2009) 
Cyclin-dependent kinase  
inhibitor (p27) 
neural differentiation, migration (Mishra et al., 2009) 
Sacsin (DNAJC29) protective against ataxin-1 toxicity (Greer et al., 2010) 
Arc/Arg3.1 regulates level of AMPAR at cell surface   (Greer et al., 2010) 
Ephexin5 negatively regulates excitatory synapse 
number and dendritic spine density 
(Margolis et al., 2010) 
Ring1B transcriptional repressor (Zaaroor-Regev et al., 2010) 
Peroxiredoxin 1 role in antioxidant protection (Nasu et al., 2010) 
Mitogen-activated protein  
kinase 6 (MAPK6) 
dendrite development and spine formation (Martinez-Noel et al., 2012) 
Hypoxia-inducible factor  
1-alpha inhibitor (HIF1AN) 
facilitate metabolic adaptation to hypoxia by 
regulating HIF1 
(Martinez-Noel et al., 2012) 
NEURL4 mediates protein-protein interactions, 
regulation of centrosome 
(Martinez-Noel et al., 2012) 
GABA Transporter 1  
(GAT1) 
removes GABA from synaptic cleft (Egawa et al., 2012) 
 
Table 1-2: Potential Ube3a substrates 
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Genetic manipulation Phenotypes Reference for mouse 
parental duplication of central 
region orthologous to15q11-13 
(partial parental disomy) 
abnormal EEG activity, cortical thinning, 
juvenile hyperactivity, adult obesity, 
ataxia 
(Cattanach et al., 1997) 
deletion of ortholog to exon 2 of 
maternal UBE3A (3kb deletion) 
impaired LTP-induction and learning and 
memory, abnormal EEG including 
audiogenic seizures, ataxia, decreased 
tonic inhibition in the cerebellum, reduced 
dopamine cell number in SNc 
(Jiang et al., 1998) 
4 Mb deletion from ZFP127 to 
HERC2 
no behavior or phenotypic data available (Gabriel et al., 1999) 
deletion of orthologs to exon 15 
and 16 of maternal UBE3A gene 
impaired performance on hippocampal-
dependent tasks and LTP-induction, 
ataxia, increased seizures, abnormal 
wake/sleep EEG patterns, fast cerebellar 
oscillations 
(Miura et al., 2002) 
disruption of AS-IC by deletion to 
SNRPN 
no behavior or phenotypic data available  (Wu et al., 2006) 
1.6 Mb deletion to UBE3A, 
ATP10A, and GABRB3  
impaired motor function and learning and 
memory deficits, spontaneous seizures and 
abnormal EEG patterns, increased 
vocalization 
(Jiang et al., 2010) 
 
Table 1-3: Angelman syndrome mouse models  
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CHAPTER 2 
 
2. Ube3a is required for experience-dependent maturation of the neocortex1 
 
2.1. Overview 
Experience-dependent maturation of neocortical circuits is required for normal 
sensory and cognitive abilities, which are distorted in neurodevelopmental disorders. We 
tested whether experience-dependent neocortical modifications require Ube3a, an E3 
ubiquitin ligase whose dysregulation has been implicated in autism and Angelman syndrome. 
Using visual cortex as a model, we found that experience-dependent maturation of excitatory 
cortical circuits was severely impaired in Angelman syndrome model mice deficient in 
Ube3a. This developmental defect was associated with profound impairments in neocortical 
plasticity. Normal plasticity was preserved under conditions of sensory deprivation, but was 
rapidly lost by sensory experiences. The loss of neocortical plasticity is reversible, as late-
onset visual deprivation restored normal synaptic plasticity. Furthermore, Ube3a-deficient 
mice lacked ocular dominance plasticity in vivo when challenged with monocular 
deprivation. We conclude that Ube3a is necessary for maintaining plasticity during 
experience-dependent neocortical development and suggest that the loss of neocortical 
plasticity contributes to deficits associated with Angelman syndrome. 
                                                            
1 Yashiro, K., Riday, T.T., Condon, K.H., Roberts, A.C., Bernardo, D.R., Prakash, R., Weinberg, R.J., Ehlers, 
M.D., and Philpot, B.D. (2009). Ube3a is required for experience-dependent maturation of the neocortex. 
Nature neuroscience 12, 777-783. 
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2.2. Introduction 
Angelman syndrome is a severe hereditary mental retardation characterized by 
outwardly normal development during the first year of life with a profound absence of 
subsequent cognitive milestones, such as speech (Jiang et al., 1998; Clayton-Smith and Laan, 
2003). Angelman syndrome is caused by loss-of-function mutations or deletions in the 
maternally inherited allele of UBE3A (Rougeulle et al., 1997), a gene whose dysregulation is 
also implicated in autism (Schroer et al., 1998). UBE3A encodes a HECT domain ubiquitin 
E3 ligase that, in the brain, is expressed primarily from the maternal allele as a result of 
tissue-specific imprinting (Albrecht et al., 1997; Jiang et al., 1998; Dindot et al., 2008). The 
apparent lack of neurodegeneration (Jiang et al., 1998) and the sharp postnatal onset of 
symptoms in Angelman syndrome suggest a developmental defect in synaptic circuits 
(Zoghbi, 2003), whose origin is unknown. Mice that are deficient in maternal Ube3a show 
genetically reversible impairments in both learning and hippocampal long-term potentiation 
(LTP) (Jiang et al., 1998; Weeber et al., 2003; van Woerden et al., 2007), indicating deficits 
in synaptic plasticity. Moreover, recent studies have demonstrated that the ubiquitin 
proteasome system is involved in synaptic development and plasticity (Yi and Ehlers, 2005, 
2007), suggesting that Ube3a-mediated protein degradation may be involved in these 
processes. 
Despite a documented role of Ube3a in learning (Jiang et al., 1998; van Woerden et 
al., 2007), it is not known how Ube3a affects the neocortex, a brain region that is heavily 
sculpted through experience-dependent development and whose disruption could explain 
most Angelman syndrome deficits. Combined with the early postnatal emergence of 
Angelman syndrome–related deficits and the clinical observations that individuals with 
Angelman syndrome present behaviors that are consistent with altered sensory processing 
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(Walz and Baranek, 2006; Williams et al., 2006),  the learning deficits associated with 
Angelman syndrome led us to hypothesize that Ube3a regulates experience-dependent 
refinement of neuronal circuits dependent on sensory input. 
We used the visual cortex as a model system (Kirkwood et al., 1996; Philpot et al., 
2001; Fagiolini et al., 2003; Gianfranceschi et al., 2003; Wallace and Bear, 2004; Li et al., 
2006b) to study the role of Ube3a in experience-dependent plasticity of the neocortex in a 
maternally deficient Angelman syndrome mouse model (Ube3am-/p+). Our results 
demonstrate an unexpected role for Ube3a in maintaining synaptic plasticity in the face of 
sensory processing and suggest a basis for the learning deficits that are associated with 
Angelman syndrome. 
2.3. Results 
Reduced maturation of cortical synapses in Ube3am-/p+ mice.  Although Angelman 
syndrome model mice lacking the maternal Ube3a allele (Ube3am-/p+) show extensive loss of 
Ube3a as a result of maternal imprinting in many areas of the brain, including the 
cerebellum, hippocampus and parts of the neocortex (Albrecht et al., 1997; Jiang et al., 1998; 
Jordan and Francke, 2006; Dindot et al., 2008), it is unknown whether this also occurs in the 
visual cortex. Immunoblot analysis revealed that paternal deficiency of Ube3a (Ube3am+/p-) 
did not alter Ube3a protein levels in the hippocampus, cerebellum or visual cortex (Figure 2-
1A). In contrast, Ube3a expression was markedly reduced in Ube3am-/p+ mice compared with 
wild-type mice in all three brain regions. Consistent with previous observations (Rougeulle et 
al., 1997; Vu and Hoffman, 1997), this attenuation was brain specific, as Ube3a was highly 
expressed in the liver of both Ube3am+/p- and Ube3am-/p+ mice (Figure 2-1A). We verified 
maternal imprinting of Ube3a protein using immunohistochemistry. Ube3a immunostaining 
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was prominent in the visual cortex of wild-type mice, but was only marginally detectable in 
Ube3am-/p- and Ube3am-/p+ mice (Figure 2-1B and Supplementary Figure 2-1). In wild-type 
mice, cells that were immunopositive for the neuronal marker NeuN (Mullen et al., 1992) 
stained intensely for Ube3a (Figure 1-1B). Immunoblot analysis of whole cortex 
homogenates (Supplementary Figure 2-1) and immunohistochemistry (data not shown) 
revealed that maternal imprinting was a general feature of neocortical Ube3a expression and 
was not unique to the visual cortex. 
To determine the physiological consequences of Ube3a loss on neocortical 
development, we examined the developmental acquisition of spontaneous excitatory synaptic 
transmission by recording miniature excitatory postsynaptic currents (mEPSCs) in layer 2/3 
pyramidal neurons of visual cortex (see Supplementary Table 2-1 for intrinsic membrane 
properties of recorded neurons). Consistent with previous findings (Desai et al., 2002; Goel 
and Lee, 2007), mEPSC amplitudes decreased and frequency increased during development 
in wild-type mice (Figure 2-1C–E). Just before eye opening (postnatal day 10, P10), mEPSC 
frequency and amplitude were indistinguishable between wild-type and Ube3am-/p+ mice 
(Figure 2-1C–E). Thereafter, mEPSC frequency failed to develop normally in Ube3am-/p+ 
mice (Figure 2-1C,E). Despite reduced mEPSC frequency relative to wild-type mice (Figure 
2-1E), both mEPSC amplitude (Figure 2-1D) and the ratio of AMPA to NMDA responses 
(Supplementary Figure 2-2) were comparable between wild-type and Ube3am-/p+ mice. 
Experience-dependent maturation of synapses requires Ube3a.  Because mEPSC 
deficits began to appear after eye opening and the onset of patterned vision (P11–12 in the 
mouse), we investigated the role of visual experience in regulating the development of 
spontaneous synaptic activity in Ube3am-/p+ mice. Toward this end, we dark-reared animals 
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from P10 until P25 to deprive them of visual experience after eye opening, and compared 
mEPSC frequency and amplitude in layer 2/3 pyramidal neurons with that of normally reared 
mice (Figure 2-2A). Although dark rearing had no measurable effect on mEPSC amplitude in 
wild-type mice at P25 (Figure 2-2B,C), sensory deprivation strongly attenuated the normal 
developmental increase in mEPSC frequency in wild-type mice (Figure 2-2B,D). In contrast, 
dark rearing did not affect mEPSC amplitude (Figure 2-2B,C) or frequency (Figure 2-2B,D) 
in Ube3am-/p+ mice. Consequently, mEPSC frequency in normally reared Ube3am-/p+ mice 
was not significantly different from that of dark-reared wild-type mice (P = 0.79; Figure 2-
2D). These findings demonstrate that, although Ube3a is not necessary for the initial sensory-
independent establishment of synaptic connectivity, it is selectively required for experience-
dependent maturation of excitatory circuits. 
The decrease in mEPSC frequency raised the possibility that layer 2/3 excitatory 
synapses are functionally lost in the absence of Ube3a. To examine this further, we used 
Golgi impregnation to test for experience-dependent differences in dendritic spines (Figure 
2-2E), the anatomical site at which most excitatory synaptic connections are made 
(Nimchinsky et al., 2002). Although the spine density of layer 2/3 visual cortical pyramidal 
neurons was comparable between dark-reared wild-type and dark-reared Ube3am-/p+ mice 
(Figure 2-2F), it was significantly lower in normally reared Ube3am-/p+ mice compared with 
normally reared wild-type mice (P < 0.001; Figure 2-2F), consistent with previous 
observations in other neocortical regions of normally reared mice (Dindot et al., 2008). 
Together with our electrophysiological observations, these data demonstrate that Ube3am-/p+ 
mice are defective in the experience-dependent development of excitatory synaptic 
connections. 
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Neocortical plasticity is impaired in Ube3am-/p+ mice.  One possible explanation for 
the lack of experience-dependent synaptic development in Ube3am-/p+ mice is defective 
activity-dependent plasticity at neocortical synapses. We therefore compared the properties 
of neocortical long-term depression (LTD) and LTP at layer 2/3 synapses in visual cortex of 
wild-type and Ube3am-/p+ mice at both young ( P25) and adult ( P100) ages. Because layer 
2/3 pyramidal neurons receive major inputs from layer 4 pyramidal neurons, layer 2/3 field 
potentials were evoked by layer 4 stimulation (Figure 2-3A). We began by measuring LTD in 
young mice using a standard stimulation protocol (1 Hz for 15 min). Although LTD was 
reliably induced in young wild-type mice, it was absent in young Ube3am-/p+ mice (Figure 2-
3B). We also observed deficits in LTP induction. A relatively weak induction protocol (three 
1-s trains of 40-Hz stimulation) elicited LTP in young wild-type mice, but failed to reliably 
induce LTP in young Ube3am-/p+ mice (Figure 2-3C). To test whether the neocortex of 
Ube3am-/p+ mice was capable of expressing LTP, we also applied a strong LTP stimulation 
protocol (two 1-s trains of 100-Hz stimulation). This protocol consistently induced LTP in 
both Ube3am-/p+ and wild-type mice (Figure 2-3D). Thus, as with LTP deficits in 
hippocampus (Weeber et al., 2003; van Woerden et al., 2007), the LTP induction machinery 
is impaired in the visual cortex of Ube3am-/p+ mice and this deficit in LTP can be overcome 
with strong stimulation. Unexpectedly, the impairment in plasticity is bidirectional, as Ube3a 
was also required for the normal induction of both LTD and LTP (Figure 2-3E), indicating 
profound synaptic rigidity. 
To determine whether the plasticity deficits in Angelman syndrome mice persisted 
into adulthood, we tested LTD and LTP in adults ( P100). In adult wild-type mice, LTD 
induced by 1-Hz stimulation was absent, as expected (Kirkwood et al., 1997), whereas LTP 
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could be induced with strong stimulation (two trains of 100-Hz stimulations; Supplementary 
Figure 2-3). In adult Ube3am-/p+ mice, however, neither of these protocols were effective at 
modifying synaptic strength (Supplementary Figure 2-3). These results indicate that wild-
type mice show attenuated neocortical plasticity as they mature and that this attenuation of 
plasticity is more severe in the absence of Ube3a (compare Figure 2-3E and Supplementary 
Figure 2-3). Furthermore, these data indicate that plasticity defects in Angelman syndrome 
mice persist into adulthood. 
Sensory experience dampens plasticity in Ube3am-/p+ mice.  Visual experience can 
alter the ability to induce LTD and LTP (Kirkwood et al., 1996; Philpot et al., 2007). 
Therefore, we speculated that the LTD and LTP impairments in Ube3am-/p+ mice could result 
from an inappropriately strong downregulation of synaptic plasticity induced by visual 
experience. In this case, one would expect that mice with no previous visual experience 
would possess normal synaptic plasticity. We investigated this possibility by measuring LTD 
and LTP in young wild-type and Ube3am-/p+ mice reared in the dark (Figure 2-4A,B). Indeed, 
visual deprivation in Ube3am-/p+ mice restored the normal induction and expression of LTP 
(induced by the 40-Hz protocol) and LTD (induced by a 1-Hz protocol) (Figure 2-4C,D). 
Thus, sensory deprivation prevents synaptic plasticity impairments in Ube3am-/p+ mice. In 
other words, Ube3am-/p+ mice are born with normal LTD and LTP at neocortical synapses, 
but ongoing sensory experiences impair the induction/expression of synaptic plasticity in the 
absence of Ube3a. 
To test whether the experience-dependent loss of synaptic plasticity observed by field 
potential recordings is a result of the loss of plasticity at excitatory synapses, we conducted 
voltage-clamp recordings of excitatory currents in layer 2/3 pyramidal neurons 
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(Supplementary Figure 2-4). Consistent with the field potential recordings, 1-Hz stimulation 
paired with postsynaptic depolarization induced LTD in normally reared young (P25) wild-
type mice, but failed to reliably induce LTD in normally reared Ube3am-/p+ mice 
(Supplementary Figure 2-4). Moreover, dark rearing partially recovered LTD in Ube3am-/p+ 
mice to levels comparable to dark-reared wild-type mice (Supplementary Figure 2-4). These 
data provide further evidence that sensory-driven activity attenuates synaptic plasticity in the 
absence of Ube3a. In support of this idea, LTD was induced normally in layer 2/3 pyramidal 
neurons of Ube3am-/p+ mice at P10, before eye opening (Supplementary Figure 2-4). 
To verify that visual experience, rather than an intrinsic developmental program, 
caused the loss of plasticity in Ube3am-/p+ mice, we investigated the effect of reinstating 
sensory experience following dark rearing. To this end, we dark-reared mice until P25 and 
then provided them with 1 or 4 d of a normal visual environment (Figure 2-4E). Although 
LTD was readily induced in the layer 4 to 2/3 pathway of visual cortex in wild-type mice 
after 1 d of visual experience, LTD appeared to be reduced in Ube3am-/p+ mice (Figure 2-4F). 
After 4 d of visual experience, LTD was completely abolished in Ube3am-/p+ mice (Figure 2-
4G), indicating that relatively brief (<4 d) visual experience was sufficient to cause a loss of 
normal plasticity in Angelman syndrome mice (Figure 2-4H). 
Late deprivation recovers plasticity in Ube3am-/p+ mice.  Can sensory deprivation 
cause a recovery of plasticity in normally reared Ube3am-/p+ mice at later stages, after the 
ability to induce plasticity has already been driven down by previous sensory experience? To 
answer this question, we reared wild-type and Ube3am-/p+ mice normally until P30 (Figure 
2-5), as LTD was absent in Angelman syndrome mice by 4 weeks of age (Figure 2-3B), and 
then measured plasticity (Figure 2-5A) after the mice had been given a late-onset visual 
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deprivation (LOVD) for 10 d (Figure 2-5B). As an additional control, LTD was also 
measured in age-matched wild-type mice that had been reared normally until P40. 
We found that 1-Hz LTD was reduced at P40 in normally reared wild-type mice 
(Figure 2-5C,D), similar to previous observations of a developmental reduction at the field 
potential level in visual cortex LTD in wild-type animals (Kirkwood et al., 1997; Jiang et al., 
2007). Consistent with a recent finding that LOVD restores synaptic plasticity in adult 
animals in vivo (He et al., 2006), LOVD reinstated 1-Hz LTD in wild-type mice (Figure 2-
5C,D). Moreover, a similar level of LTD was restored after LOVD in Ube3am-/p+ mice 
(Figure 2-5C,D), suggesting that LOVD recovers LTD even in the absence of Ube3a (Figure 
2-5D). The LOVD-induced recovery of LTD was also observed in whole-cell recordings 
from identified layer 2/3 pyramidal neurons (Supplementary Figure 2-4). Together, these 
data demonstrate that LOVD can restore synaptic plasticity in Ube3am-/p+ mice. 
Ocular dominance plasticity is absent in Ube3am-/p+ mice.  The severe plasticity 
deficits recorded in ex vivo brain slices suggested that experience-dependent modifications in 
vivo might also be impaired by the absence of Ube3a. We first assessed visual function by 
recording visual evoked potentials (VEPs) in visual cortex (Figure 2-6). These measurements 
revealed that both visual acuity (Supplementary Figure 2-5) and baseline ocularity were 
normal (Figure 2-6B,C), suggesting that Ube3am-/p+ mice have grossly normal visual 
functions. 
Next, we investigated in vivo plasticity of visual cortical circuits by challenging the 
mice with monocular deprivation (Figure 2-6A). This sensory manipulation produces a well-
characterized ocular dominance shift in wild-type animals and serves as a gauge of critical 
period plasticity (Wiesel and Hubel, 1963). In the visual cortex, an ocular dominance shift 
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can be observed most prominently during a critical period, which peaks in the third to fourth 
postnatal week in mice (Gordon and Stryker, 1996). At these ages, however, both LTD and 
LTP were impaired in normally reared Ube3am-/p+ mice (Figure 2-3). In wild-type mice 
experiencing normal binocular vision, we observed no marked change in ocularity from P27–
P30, as expected (Figure 2-6B). However, 3 d of monocular deprivation beginning from P27 
reduced the contralateral bias of wild-type mice (Figure 2-6B), an effect that was particularly 
robust when comparisons were made between monocularly deprived mice and their age-
matched, non-deprived controls (t test between monocularly deprived wild-type mice and 
age-matched control wild-type mice, P < 0.005). In these experiments, eye occlusion was 
always contralateral to the recording electrode. These data indicate that wild-type mice are 
highly susceptible to altered sensory experience at this age. 
Ube3am-/p+ mice experiencing binocular vision had similar ocularity on P27 and P30 
(Figure 2-6C). Unlike wild-type mice, the Ube3a-deficient mice showed no response to 3 d 
of monocular deprivation (Figure 2-6C). The ocularity change observed in wild-type mice 
was largely a result of monocular deprivation–induced depression of the contralateral VEP 
response (Figure 2-6D). No change in the contralateral response was observed in Ube3am-/p+ 
mice (Figure 2-6E). These results suggest that the experience-dependent loss of synaptic 
plasticity that occurs in the absence of Ube3a likewise limits the ability to rearrange cortical 
circuits during the critical period in vivo. 
2.4. Discussion 
We have identified a critical role for the Angelman syndrome– and autism-linked 
ubiquitin ligase Ube3a in experience-dependent neocortical development. We found that 
visual experience failed to strengthen functional connectivity of excitatory neurons in the 
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visual cortex of Ube3am-/p+ mice. The lack of experience-dependent development of 
excitatory circuits is probably caused by deficits in synaptic plasticity, as both LTP and LTD 
were severely attenuated in Ube3am-/p+ mice. Paradoxically, the plasticity deficit is itself 
driven by sensory experiences, as sensory deprivation prevented the loss of normal synaptic 
plasticity, whereas brief sensory experiences could reinstate the plasticity deficit. Therefore, 
Ube3a is necessary to maintain normal synaptic plasticity during ongoing activity-dependent 
remodeling. Finally, we found that Ube3am-/p+ mice lacked the cortical plasticity that is 
normally induced by monocular deprivation in vivo, demonstrating a role for Ube3a in 
naturally occurring experience-dependent modifications of neuronal circuits. The neocortical 
plasticity deficits caused by the absence of Ube3a may thus underlie the learning deficits 
observed in Angelman syndrome. 
Two possibilities could explain the plasticity deficits in Ube3am-/p+ mice. First, 
cooperative excitatory drive may be attenuated in Ube3a-deficient mice, thus increasing the 
induction parameters for LTD and LTP. This could arise from a decrease in the number of 
excitatory synapses or their release probability, both of which are consistent with the 
observed reduction in spine density and mEPSC frequency of layer 2/3 pyramidal neurons. 
The possibility that Ube3am-/p+ mice have abnormal neurotransmitter release might be 
particularly relevant for the LTD deficit in layers 2/3, as recent evidence suggests that LTD 
induced at this synapse requires endocannabinoid-mediated reductions in presynaptic 
neurotransmitter release (Crozier et al., 2007). Future studies are needed to determine 
whether presynaptic plasticity and/or release mechanisms are disrupted by the absence of 
Ube3a, and whether this might contribute to the observed plasticity deficits. 
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Alternatively, the machinery for plasticity induction or expression may itself be 
compromised in Ube3a-deficient mice, including changes in calcium entry, receptor 
trafficking or pre/postsynaptic signaling molecules. Indeed, the absence of Ube3a impairs the 
function of calcium/calmodulin-dependent protein kinase II (CaMKII) (Weeber et al., 2003), 
an enzyme that normally facilitates LTP induction (Xia and Storm, 2005) in both the 
hippocampus (Silva et al., 1992) and visual cortex (Kirkwood et al., 1997; Frankland et al., 
2001). Thus, although it has not yet been examined in the neocortex, reductions in CaMKII 
activity in Ube3am-/p+ mice might contribute to the observed deficits in neocortical LTP. 
Notably, the cortical LTP deficit observed in Camk2a-/- mice becomes progressively more 
severe with development (Kirkwood et al., 1997), raising the possibility that the age-
dependent increase in the LTP deficits observed in Ube3a-deficient mice may be a 
consequence of an increasing requirement of CaMKII for LTP induction (Yasuda et al., 
2003). Similar to LTP, impairments in LTD could also arise from changes in signaling 
molecules. One such candidate molecule is protein phosphatase 1, as its enzymatic activity is 
implicated in LTD induction (Mulkey et al., 1994; Torii et al., 1995) and is attenuated in 
Ube3am-/p+ mice (Weeber et al., 2003). If the plasticity induction mechanisms for LTD and 
LTP are indeed compromised in the neocortex in the absence of Ube3a, then this could 
contribute to the observed reductions in spine density. 
The ubiquitin-proteasome system is necessary for both LTP (Fonseca et al., 2006) and 
LTD (Colledge et al., 2003), and our data demonstrate that Ube3a is a critical component of 
this system. However, the protein substrates of Ube3a, the degradation of which is required 
to maintain normal synaptic plasticity, remain unknown. Extensive GeneChip analyses of the 
murine visual cortex have revealed that visual experience affects the expression of many 
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genes (Majdan and Shatz, 2006; Tropea et al., 2006). If one of these visual experience–
induced proteins is a substrate for Ube3a, this protein could be abnormally overexpressed in 
Ube3am-/p+ mice that are given visual experience. Furthermore, if the protein has an ability to 
suppress synaptic plasticity, experience-dependent accumulation of such a protein would 
attenuate LTD and LTP in the absence of Ube3a. An ideal substrate of Ube3a that could 
account directly for the experience-induced plasticity deficits would thus be a protein that is 
upregulated by activity, but suppresses subsequent synaptic remodeling at high levels. 
We suggest that the plasticity deficits observed in vitro may contribute to or underlie 
synaptic learning deficits associated with Angelman syndrome. In support of the idea that 
Ube3a is required for naturally occurring plasticity during a critical period of development, 
we found that ocular dominance plasticity was absent in Ube3am-/p+ mice (Figure 2-6). 
Because LTD and monocular deprivation-induced depression of the deprived eye response 
share a common pathway (Heynen et al., 2003), visual experience–induced loss of LTD 
could be the direct cause of the lack of ocular dominance plasticity. Consistent with this idea, 
Ube3a-deficient mice lacked the loss of responsiveness from the deprived eye that is 
normally observed following brief monocular deprivation. 
Functional (Thompson et al., 1999; Van Splunder et al., 2003) and anatomical (Jay et 
al., 1991) abnormalities in the visual system of individuals with Angelman syndrome are 
consistent with the observed aberrant development of visual cortical circuits in Ube3am-/p+ 
mice. If the deficits in experience-dependent encoding in the visual cortex can be generalized 
to other areas of the brain, then these same changes in synaptic physiology may explain the 
observed deficiencies in learning and cognition in individuals with Angelman syndrome. It is 
notable that LOVD restored plasticity in Ube3am-/p+ mice (Figure 2-5 and Supplementary 
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Figure 2-4). This demonstration that the physiological substrates of synaptic plasticity remain 
intact raises the possibility that behavioral or pharmacological manipulations could improve 
brain function in individuals with Angelman syndrome. Moreover, because it has been 
speculated that sensory experience–dependent brain development is abnormal in other 
neurodevelopmental disorders, such as Rett syndrome, Fragile X syndrome and autism 
(Zoghbi, 2003), our experimental approach may help to elucidate the roles of experience in 
these disorders. 
2.5. Methods 
Animals. 
Mice deficient in Ube3a, developed previously (Jiang et al., 1998), were obtained 
through Jackson Laboratory. Mice were bred on a 129S7 background. To obtain 
heterozygous mice lacking the Ube3a gene paternally (m+/p–) or maternally (m–/p+), we 
crossed a heterozygous male or female mouse with a wild-type female or male mouse, 
respectively. For most electrophysiological recordings in slices, WT and maternal 
heterozygous mice were used in three age groups: infant (P8–11, P10), young (P21–28, 
P25) and adult (P94–121, P100). For LOVD experiments, WT and maternal heterozygous 
mice at P40 (P37–40) were used. Control mice were raised on a 12-h light/dark cycle, 
whereas dark-reared mice were raised in complete darkness from P9–11 (before eye opening) 
until P25. Light exposure was achieved by transferring dark-reared mice into the control 
condition at P21–28 and providing 1–4 d in the normal light/dark cycle. LOVD was achieved 
by transferring NR mice at P30 into complete darkness for 10 d. Electrophysiological 
recordings were obtained from at least three mice for each condition. For in vivo 
electrophysiological recordings, mice were used at ages indicated below. All animal 
26 
 
procedures were performed in compliance with the US Department of Health and Human 
Services and the animal care guidelines at the University of North Carolina and Duke 
University. 
Immunoblot analysis. 
Tissue lysates were prepared in lysis buffer containing 50 mM Tris, 150 mM NaCl, 
50 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100 (vol/vol), pH 7.4, and a cocktail 
of protease and phosphatase inhibitors. Protein concentrations were determined using DC 
Protein Assay (BioRad). We resolved 20 g of each lysate on a 7.5% Tris-HCl gel (BioRad) 
and transferred them to a PVDF membrane. The membrane was probed with antibody to 
Ube3a (1:1,000, Bethyl Labs) and subsequently with horseradish peroxidase–conjugated 
polyclonal antibody to rabbit (1:10,000, Cell Signaling). Signals were visualized with ECL 
Plus reagent (Amersham) and an LAS-3000 Intelligent Dark Box (FujiFilm). 
Immunohistochemistry. 
Mice were anesthetized with pentobarbital and perfused intracardially with cold 
phosphate-buffered saline followed by freshly prepared 4% paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4). Brains were postfixed in the same solution overnight at 4 °C. 
Brains were then cut into 50- m coronal sections using a vibratome (Leica Microsystems). 
For immunohistochemistry experiments, sections from wild-type, Ube3am-/p+ and Ube3am–/p– 
mice were always processed simultaneously. Sections were incubated in 10 mM sodium 
citrate buffer (pH 8.65) at 80 °C for 15 min before the immunoreactions. Sections were 
incubated with rabbit polyclonal antibody to Ube3a (1:500, Bethyl Labs) and mouse 
monoclonal antibody to NeuN (1:3,000, Chemicon) overnight at 4 °C, and then incubated 
with Alexa Fluor 488 goat antibody to mouse IgG and Alexa Fluor 568 goat antibody to 
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rabbit IgG (1:500, Invitrogen). Images were acquired using a Zeiss LSM 510 laser-scanning 
confocal microscope. 
Visual cortical slice preparation. 
Mice were anesthetized with an overdose of pentobarbital and decapitated after the 
disappearance of corneal reflexes. Brains were dissected rapidly and the visual cortex cut 
coronally at 300 m (voltage-clamp recordings) or 400 m (field potential recordings) in 
dissection buffer containing 75 mM sucrose, 87 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 
26 mM NaHCO3, 10 mM glucose, 7 mM MgCl2, 0.5 mM CaCl2 and 1.3 mM ascorbic acid. 
Prior to recordings, slices were allowed to recover for 1 h in a submersion chamber 
containing oxygenated artificial cerebrospinal fluid (ACSF), which consisted of 124 mM 
NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 20 mM glucose, 2 mM MgCl2 and 1 
mM CaCl2. For patch-clamp recordings, slices were allowed to recover in a submersion 
chamber, which was preheated to 35 °C and gradually cooled to room temperature (23 1 
°C). For field recordings, slices were allowed to recover in a submersion chamber, which was 
precooled to 5–10 °C and gradually warmed to room temperature (23 1 °C). 
Voltage-clamp recordings. 
For mEPSC recordings, slices were placed in a submersion chamber, maintained at 30 
°C and perfused at 2 ml min-1 with oxygenated ACSF supplemented with 200 nM 
tetrodotoxin, 100 M DL-2-amino-5-phosphonovaleric acid and 50 M picrotoxin. Neurons 
were visualized with a Carl Zeiss Axioskop equipped with infrared differential interference 
contrast optics. Patch pipettes were pulled from thick-walled borosilicate glass. Open tip 
resistances were 3–5 M  when pipettes were filled with an internal solution containing 20 
mM KCl, 100 mM potassium gluconate, 10 mM potassium HEPES, 4 mM MgATP, 0.3 mM 
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NaGTP, 10 mM sodium phosphocreatine and 0.01% Alexa 488 (wt/vol), adjusted with KOH 
to pH 7.4, and with sucrose to 290–300 mOsm. Voltage-clamp recordings were performed in 
the whole-cell configuration with a patch-clamp amplifier (Multiclamp 700A, Molecular 
Devices), and data were acquired with pClamp 9.2 software (Molecular Devices). Input and 
series resistances were determined throughout the experiment by measuring the response to 
small intermittent test pulses. Recordings were discarded if the series resistance grew larger 
than 25 M , or the resting potential was more positive than -60 mV (for the recordings in 
infant mice, the resting potential was not used as a criterion, as many neurons typically 
exhibit resting potentials higher than -60 mV). Analysis was restricted to neurons that were 
anatomically verified by intracellular fills to be pyramidal neurons. MiniAnalysis 
(Synaptosoft) was used to detect and measure mEPSCs. The threshold to detect mEPSC was 
set at 5 pA, which is more than 2.5-fold greater than the root mean square of the noise, and 
mEPSCs with 10-90% rise times more than 3 ms were excluded from the analysis. Analysis 
of mEPSCs was performed blind to age, genotype and rearing condition. 
Whole-cell LTD induction.  
Recording conditions were the same as for the mEPSC recordings, except that ACSF 
was not supplemented with tetrodotoxin, APV, and picrotoxin, and the internal solution 
contained (in mM): 107 CsOH, 107 Gluconic acid, 20 (K)HEPES, 0.2 (K)EGTA, 3.7 NaCl, 5 
QX-314, 4 (Mg)ATP, 0.3 (Na)GTP, 10 Na-phosphocreatine and 0.01% w/v Alexa 488, 
adjusted to pH 7.2, and with sucrose to 290 mOsm.  An empirically determined liquid-
junction potential (approximately -14 mV) was corrected.  EPSCs were elicited with a two-
conductor cluster electrode (FHC) placed in layer 4.  Test stimuli (200 μsec) were delivered 
at 0.033 Hz. The test holding potential was −67 mV (reversal potential for Cl-).  Low 
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frequency stimulus long-term depression (LFS-LTD) was induced by pairing 1 Hz 
presynaptic stimulation with a brief (100 msec) postsynaptic step depolarization from −67 to 
−47 mV for each of 200 pulses.  Each presynaptic stimulation occurred midway (50 msec) 
into the step depolarization.  Experiments were discarded if input resistance was < 200 MΩ 
(younger mice) or < 100 MΩ (~P40), if series resistance was > 25 MΩ, or if series resistance 
changed by >30% during the recording.  
Ratio of AMPA receptor to NMDA receptor-mediated currents. 
Recording conditions were the same as for the LTD induction experiments except 
ACSF contained 2 mM MgCl2, 1 µM glycine, and 50 µM picrotoxin, and internal solution 
contained (in mM): 102 CsOH, 102 Gluconic acid, 5 TEA-chloride, 3.7 NaCl, 20 (K)HEPES, 
0.3 (Na)GTP, 4 (Mg)ATP, 0.2 (K)EGTA, 10 BAPTA, 5 N-(2,6-dimethylphenyl 
carboylmethyl) triethylammonium bromide (QX-314) chloride (Alomone Labs), and 0.01% 
w/v Alexa 488, adjusted to pH 7.2 and to osmolarity  300 mmol/kg.  An empirically 
determined liquid-junction potential (approximately −16 mV) was corrected.  EPSCs were 
elicited with a two-conductor cluster electrode (FHC) placed in layer 4.  Test stimuli (50 
μsec) were delivered at 0.066 Hz and evoked EPSCs were recorded at -96 mV and +44 mV.  
Peaks of an evoked EPSC at -96 mV were considered AMPA receptor-mediated.  NMDA 
receptor-mediated currents were recorded at +44 mV and measured 50 ms after a stimulation 
artifact, a time when AMPA receptor-mediated currents are largely absent.  Experiments 
were discarded if input resistance was < 200 MΩ or series resistance was > 25 MΩ measured 
at -96 mV.  
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Field potential recordings. 
Slices were maintained at 30 °C and perfused with ACSF at a rate of 2 ml min-1. A 
concentric bipolar tungsten stimulation electrode was positioned in layer 4 and a glass 
recording electrode (1–3 M ) that was filled with ACSF was positioned in layers 2/3. The 
magnitude of responses evoked by a 200- s pulse was monitored by the amplitude of the 
field potential. Stimulation intensity was adjusted to elicit half the maximal response, and 
stable baseline responses were elicited every 30 s. The resulting signals were filtered between 
0.1 Hz and 3 kHz, amplified, and captured at 10 kHz using pCLAMP 9.2 software 
(Molecular Devices). After achieving a stable baseline (<5% drift) for 15 min, slices were 
stimulated with one of the following three protocols: 100-Hz stimulation for 1 s (repeated 
two times with a 15-s interval), 40-Hz stimulation for 1 s (repeated three times with 10-s 
intervals) or 900 pulses at 1 Hz. fEPSP amplitudes were recorded every 30 s for 45 min 
following cessation of the stimulation protocol. Control and experimental subjects were run 
in an interleaved fashion. Normalized averaged data were reported as means s.e.m. Changes 
in synaptic strength were measured by comparing the average response amplitudes 30–45 
min after conditioning stimulation to the pre-conditioning baseline response. 
Morphological analysis by Golgi staining. 
Littermates at P25–26 reared in a normal environment (NR WT, n = 4 mice; NR 
Ube3am-/p+, n = 3 mice) or in complete darkness from P10 (DR WT, n = 3 mice; DR Ube3am-
/p+, n = 4 mice) were used for morphological analysis. Mice were anesthetized with 
pentobarbital and killed by intracardial perfusion of cold phosphate-buffered saline followed 
by freshly prepared 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). After post-
fixation in the same solution, tissue blocks containing visual cortex were processed according 
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to a modification of the Golgi-Kopsch technique (Gatenby J.B., 1950). We collected 100-
m-thick serial sections for study. Pyramidal neurons at layer 2/3 of the visual cortex were 
chosen and spines in 13- m dendritic segments taken 30–50 m from the soma were counted 
under a 100 oil-immersion lens. Analyses were performed blind to genotype. Images were 
taken on a Leica TCS SP2 laser scanning confocal microscope using the 488-nm laser line as 
a light source. To obtain high-resolution images of impregnated dendrites, we took stacks 
with a 100 objective at 0.3663- m intervals at 4 zoom. Dendritic segments were cropped 
from the resulting stacks and processed by three-dimensional deconvolution using the 
AutoQuant software (Media Cybernetics). 
Visual evoked potential recordings. 
Male and female mice were anesthetized with ketamine/xylazine (120 and 9 mg per 
kg, respectively; intraperitoneal, Southern Anesthesia) and locally at the scalp incision site 
with 0.25% bupivacaine (Hospira). Tungsten microelectrodes (FHC) with tip impedances of 
0.3–0.5 M  were stereotaxically implanted in the binocular zone of the visual cortex: 0.0 
mm lambda (anterior/posterior), 3.00 mm sagittal (medial/lateral) and -0.45 mm depth 
(dorsal/ventral). Silver reference electrodes were implanted -1.0 mm anterior/posterior to 
bregma and 2.00 mm sagittal at a depth just touching the brain surface. Electrodes were 
secured to the skull with Loctite 455 cyanoacrylate (Henkel). 
Electrodes were implanted at P22–23 and animals were habituated 24 h before the 
first recording session at P27–28. Visual stimuli consisted of full-field diagonal (135° or 45°, 
reversed on day 3) sine wave gratings at 0.3 cpd and 100% contrast. Visual potentials were 
evoked monocularly through the eye ipsilateral and contralateral to the recording electrode. 
Following baseline ocularity VEP recordings, one eye was sutured closed. Mice were 
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anesthetized with 1.5% isoflurane, lid margins were trimmed and three stitches were applied 
along the length of the lids using 5-0 silk. Mice were monocularly deprived in the eye 
contralateral to the recording electrode for 3 d. The stitched eye was then reopened and visual 
potentials were again evoked monocularly through the eye ipsilateral and contralateral to the 
recording electrode to measure the ocular dominance shift. To quantify ocular dominance 
plasticity, we took measurements as a ratio of the contralateral (deprived) to ipsilateral 
(nondeprived) eye responses (Figure 2-6B,C) or as raw amplitudes (Figure 2-6D,E). As a 
control for developmental changes, VEP recordings were performed in mice that did not 
receive monocular deprivation. 
Visual acuity. 
Measurements were conducted in awake mice at P34.  Electrodes were implanted at 
P22 and animals were habituated to the restraint apparatus 24 h prior to the first recording 
session.  Electrical signals were amplified, band pass filtered (0.3-100 Hz), digitized, and 
averaged (160 events in two blocks) in synchrony with the stimulus contrast reversal.  Peak-
to-trough amplitude was measured for transient VEPs in response to abrupt contrast reversal 
(1 Hz).  Visual stimuli consisted of full-field horizontal sine wave gratings [0.05-0.95 cycles 
per degree (cpd) presented in randomized order] at maximal contrast.  Responses to 0% 
contrast (gray screen) were also recorded as a measure of activity not evoked by patterned 
visual stimuli.  Animals were positioned 20 cm away from a 21” CRT (23 cd/m2 mean 
luminescence) centered on the midline. 
Statistics. 
Data are expressed as the means s.e.m. Unless otherwise noted, unpaired two-tailed 
Student's t-tests were used to test for statistical significance, which was placed at P < 0.05. 
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The raw values of the data shown in Figures 2-1, 2-2, 2-3, 2-4, 2-5, and 2-6 can be found in 
Supplementary Table 2-2. 
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Figure 2-1: Reduced functional maturation of neocortical synapses in Angelman 
syndrome mice. (a) Immunoblot analysis of Ube3a in tissue from young (P26) wild-type 
(WT), Ube3am+/p- and Ube3am-/p+ mice. (b) Immunohistochemical analysis of Ube3a 
expression in the visual cortex from young (P24) WT and Ube3am-/p+ mice. Strong Ube3a 
immunoreactivity was observed in layer 2/3 (L2/3) neurons of WT mice. NeuN antibody 
stains the cell bodies of neurons. Scale bar represents 50 m. (c) Representative traces of 
mEPSCs recorded in L2/3 pyramidal neurons from WT or Ube3am-/p+ mice at P10, P25 
and P100. Scale bars represent 0.2 s and 20 pA. (d) Average mEPSC amplitude as a 
function of postnatal age in WT (P10, n = 11 cells; P25, n = 11 cells; P100, n = 12 cells) and 
Ube3am-/p+ mice (P10, n = 11 cells; P25, n = 12 cells; P100, n = 12 cells). (e) Average 
mEPSC frequency as a function of postnatal age in WT and Ube3am-/p+. *P < 0.05 and **P < 
0.005. Error bars represent s.e.m. 
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Figure 2-2: Sensory experience augments excitatory synaptic connections in the 
neocortex of WT mice, but not Angelman syndrome mice. (A) Schematic for the rearing 
conditions. Normally reared (NR) mice were maintained in a 12-h consecutive dark/light 
cycle, and dark-reared (DR) mice were kept in complete darkness from P10. (B) 
Representative traces of mEPSCs recorded in layer 2/3 pyramidal neurons in young WT or 
Ube3am-/p+ mice reared normally or in complete darkness. Scale bars represent 0.2 s and 20 
pA. (C) Dark rearing did not affect mEPSC amplitude in WT (DR, n = 12 cells; NR, n = 11 
cells; P = 0.68) or Ube3am-/p+ mice (DR, n = 14 cells; NR, n = 12 cells; P = 0.16). (D) Dark 
rearing significantly reduced mEPSC frequency in WT mice (P < 0.005), but did not affect 
mEPSC frequency in Ube3am-/p+ mice (P = 0.46). (E) Representative images of basal 
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dendrites of layer 2/3 pyramidal neurons visualized with Golgi staining. Scale bar represents 
10 m. (F) Average density of dendritic spines in DR (WT, n = 25 cells; Ube3am-/p+, n = 25 
cells; P = 0.15) and in NR mice (WT, n = 33 cells; Ube3am-/p+, n = 32 cells; P < 0.001). **P < 
0.005 and ***P < 0.001. Error bars represent s.e.m. 
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Figure 2-3: Synaptic plasticity is impaired bidirectionally in the neocortex of Angelman 
syndrome mice. (A) Schematic diagram of stimulating (S) and recording (R) configuration. 
(B) Baseline synaptic responses of WT and Ube3am-/p+ mice were measured before and after 
application of conditioning stimuli to the layer 4 (L4) to L2/3 pathway of the visual cortex. 
Top traces are representative averaged traces of a 15-min baseline (1), 30–45-min period 
after LTD induction (2) and their overlays (1, 2). Scale bars represent 10 ms and 1 mV. The 
bottom graph describes the average change in field excitatory postsynaptic potential (fEPSP) 
on delivery of a 1-Hz stimulus (indicated by the bar). Although 1-Hz stimulation for 15 min 
induced LTD in young WT mice, it did not change fEPSP amplitudes in Ube3am-/p+ mice 
(WT, n = 13 slices; Ube3am-/p+, n = 7 slices; P < 0.04). (C) Data are presented as in B, except 
that a stimulus consisting of three 40-Hz trains was delivered (indicated by an arrow). 
Although this stimulation induced LTP in WT mice, it did not alter fEPSP amplitudes in 
Ube3am-/p+ mice (WT, n = 12 slices; Ube3am-/p+, n = 10 slices; P < 0.02). (D) Data are 
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presented as in C, except that the stimulus consisted of two 100-Hz trains (indicated by an 
arrow). This stimulation induced LTP in both genotypes (WT, n = 12 slices; Ube3am-/p+, n = 
10 slices; P = 0.59). (E) Frequency-response functions derived from visual cortex of WT and 
Ube3am-/p+ mice. Data points represent percent changes in fEPSP 30–45 min after the 
delivery of conditioning stimuli. The data points for 0.033 Hz are inferred from baseline 
stimulation delivered once every 30 s, which induced no obvious synaptic modifications. *P 
< 0.05. Error bars represent s.e.m. 
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Figure 2-4: Sensory experience eliminates neocortical plasticity in Angelman syndrome 
mice. (A) Schematic of the recording configuration. (B) Schematic of the dark-rearing 
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condition. (C) Representative waveforms and averaged data demonstrating that the level of 
LTP induced with 40-Hz stimulation was comparable between WT (n = 18) and Ube3am-/p+ 
(n = 18) mice reared in complete darkness (P = 0.91). Scale bars represent 10 ms and 0.5 
mV. (D) The level of LTD was also comparable between WT and Ube3am-/p+ DR mice (WT, 
n = 16 slices; Ube3am-/p+, n = 17 slices; P = 0.69). (E) Schematic showing the schedule for 
exposing DR mice to light. (F) Dark rearing, followed by 1 d of normal rearing attenuated 
LTD in visual cortical slices from Ube3am-/p+ mice (WT, n = 19; Ube3am-/p+, n = 15; P = 
0.08). (G) After dark rearing, 4 d of normal rearing completely suppressed LTD in visual 
cortical slices from Ube3am-/p+ mice (WT, n = 9; Ube3am-/p+, n = 6; P < 0.01). (H) Visual 
experience dampened LTD in the visual cortex of Ube3am-/p+ mice. Data represent means 
s.e.m. of the percent reduction in fEPSP 30–45 min after the delivery of conditioning stimuli 
measured in NR and DR mice and in dark-then-light exposed for 1 or 4 d (DR+1L and 
DR+4L) mice. *P < 0.05. Error bars represent s.e.m. 
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Figure 2-5: LOVD restores synaptic plasticity in Angelman syndrome mice. (A) 
Schematic of the recording configuration. (B) Schematic for the LOVD-rearing condition. 
(C) Averaged data demonstrating that LTD was abolished in NR WT mice at P40, whereas 
LTD of a similar magnitude was induced after LOVD in WT and Ube3am-/p+ mice (NR WT, 
n = 10 slices; LOVD WT, n = 10 slices; LOVD Ube3am-/p+, n = 11 slices; P < 0.05, NR WT 
was significantly different from both LOVD WT and LOVD Ube3am-/p+, one-way ANOVA 
followed by Tukey). (D) Bar graph of data shown in c. *P < 0.05. Error bars represent s.e.m. 
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Figure 2-6: Critical period ocular dominance plasticity is absent in Angelman syndrome 
mice. (A) Schedule of the surgery and recording. (B) Changes in the ratio of contralateral to 
ipsilateral eye responses (C/I ratio) in monocularly deprived (MD, n = 13 mice) and 
nondeprived control WT mice (n = 14 mice) from P27 (day 0) to P30 (day 3). After 3 d of 
monocular deprivation, the C/I ratio was significantly reduced (paired t test, P < 0.01), 
whereas this reduction was not observed in age-matched nondeprived controls (paired t test, 
P = 0.14). (C) C/I ratios in Ube3am-/p+ mice (MD = 11 mice, control = 9 mice). Monocular 
deprivation did not affect the C/I ratio (paired t test, P = 0.52). C/I ratio was stable for 3 d in 
age-matched nondeprived controls (paired t test, P = 0.53). (D) Monocular deprivation–
induced changes in contralateral, but not ipsilateral, VEPs in WT mice. Top traces are 
representative waveforms of VEPs recorded in WT mice. Scale bars represent 50 V and 50 
ms. The bottom graph describes comparisons of VEP amplitudes between control (N, 
normal) and MD WT mice. *P < 0.05. (E) Data is presented as in D, except that experiments 
were conducted in Ube3am-/p+ mice. Error bars represent s.e.m. 
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Supplementary Figure 2-1: Maternal expression of Ube3a in the cortex. (A) 
Immunohistochemical analysis of Ube3a expression in the visual cortex from young (P24) 
WT, Ube3am-/p+, and Ube3a m-/p- mice. Whereas strong Ube3a immunoreactivity was 
observed in all cortical layers except for layer 1 (L1) and white matter (WM) in WT 
mice, it was very weak in both Ube3am-/p+ and Ube3am-/p- mice. NeuN antibody stains 
neuronal cell bodies. Scale bars, 100 μm. (B), Immunoblot analysis of Ube3a expression in 
whole cortical lysates from WT and Ube3am-/p+ mice at P25-27. Each lane contains cortical 
lysate from a different mouse. β-tubulin was used as an expression control. 
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Supplementary Figure 2-2: The ratio of AMPA receptor- to NMDA receptor-mediated 
currents is normal in Ube3am-/p+ mice. (A), Example traces: EPSCs were evoked by 
stimulating layer 4 and recording in layer 2/3 pyramidal neurons while cells were voltage-
clamped at either 96 mV or +44 mV. AMPA receptor-mediated currents were measured at 
the EPSC peak, while NMDA receptor-mediated currents were recorded at +44 mV and 
measured 50 msec after the stimulus artifact. Scale bars: WT 50 msec, 50 pA; Ube3am-/p+, 50 
msec, 100 pA. (B), Average AMPA/NMDA current ratios for WT (n = 16 cells) and Ube3am-
/p+ mice (n = 11 cells), showing no significant difference (WT, 1.4 ± 0.2; Ube3am-/p+, 1.4 ± 
0.1; p = 0.89). 
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Supplementary Figure 2-3: The absence of Ube3a causes deficits in bidirectional 
synaptic plasticity in the visual cortex of adult mice. (A) Schematic of the recording 
configuration. (B) Synaptic responses of WT (open circle) and Ube3am-/p+ (closed triangle) 
mice were measured before and after application of a conditioning stimulation to the layer 4 
(L4) to L2/3 pathway of the visual cortex. LTD was induced with 1 Hz stimulation for 15 
min in visual cortex slices from adult mice. Top traces are representative averaged traces of 
15 min baseline (1), 30-45 min period after LTD induction, (2) and their overlays (1, 2). 
Scale bars: 5 ms, 1 mV. Bottom graph describes average change in field EPSP (Percentage 
fEPSP) upon delivery of a 1 Hz stimulus (indicated by the bar) (WT, 97.1 ± 7.1%; Ube3am-
/p+, 100.5 ± 8.0%; n = 9, 9; p = 0.75). LTD was not induced in either genotype. (C) Same as 
b, except that plasticity-inducing stimulation consisted of three 40 Hz trains (indicated by an 
arrow). Whereas this stimulation induced a weak LTP in WT mice, it failed to do so in 
Ube3am-/p+ mice (WT 109.2 ± 4.0%; Ube3am-/p+, 104.4 ± 3.7 %; n = 10, 8 slices; p = 0.39). 
(D) Same as c, except that the LTP-inducing stimulation consisted of two 100 Hz trains 
(indicated by an arrow). Whereas this stimulation induced strong LTP in WT mice, it did not 
alter fEPSP amplitudes in Ube3am-/p+ mice (WT, 117.3 ± 2.4 %; Ube3am-/p+, 102.4 ± 4.3%; n 
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= 6, 7 slices; p < 0.02). (E), Frequency-response functions derived from visual cortex of WT 
and Ube3am-/p+ mice. Data points represent percent changes in fEPSP 30-45 min after the 
delivery of conditioning stimulations. The data points for 0.033 Hz are inferred from baseline 
stimulation delivered once every 30 sec, which induced no obvious synaptic modifications. 
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Supplementary Figure 2-4: Experience-dependent loss of LTD at excitatory synapses 
onto layer 2/3 pyramidal neurons in AS mice. (A) Whole-cell recording configuration: 
EPSCs evoked at layer 4 (L4) were recorded in L2/3 pyramidal neurons. (B) LTD induction 
protocol. (C) Baseline synaptic responses of WT (open circle) and Ube3am- /p+ (closed 
triangle) mice were measured before and after application of conditioning stimuli in normally 
reared (NR) mice at ~P10. A top schematic describes rearing condition. Traces in the middle 
are representative averaged traces of 5 min baseline (1), 25-30 min period after LTD 
induction (2), and their overlays (1, 2). Scale bars: 20 ms, 100 pA. Bottom graph describes 
average change in EPSC (Percentage EPSC) upon delivery of the conditioning stimulus 
(indicated by the bar). The pairing protocol induced LTD in both WT and Ube3am-/p+ mice 
(Percentage EPSC: WT, 75.3 ± 11.5, n = 8 cells; Ube3am-/p+, 68.4 ± 13.5, n = 8 cells; p = 
0.71). (D) Same as C, except that LTD was measured in young (~P25) mice reared normally 
(left) or in a complete darkness (right). In normally reared mice (NR), whereas the pairing 
protocol induced LTD in WT mice, it did not alter EPSC amplitudes in Ube3am-/p+ mice 
(Percentage EPSC: WT, 62.3 ± 6.1, n = 11 cells; Ube3am-/p+, 90.1 ± 10.1, n = 9 cells; p < 
0.03). In dark-reared (DR) mice, LTD was equally induced in both WT and Ube3am-/p+ mice 
(Percentage EPSC: WT, 62.7 ± 9.1, n = 7 cells; Ube3am-/p+, 74.7 ± 5.9 , n = 7 cells; p = 0.30). 
(E) Same as C, except that LTD was measured in ~P40 mice, provided with late-onset visual 
deprivation (LOVD). LTD was equally induced in both WT and Ube3am-/p+ mice (Percentage 
EPSC: WT, 63.1 ± 5.4, n = 9 cells; Ube3am-/p+, 25.6 ± 9.5, n = 6 cells; p = 0.30). (F) Visual 
experience causes developmental loss of LTD in Ube3am-/p+ mice. Data represent means ± 
SEM of percentage LTD measured 25-30 min after the delivery of conditioning stimuli. 
Whereas LTD was comparable between WT and Ube3am-/p+ mice at P10, it was reduced in 
young (~P25) Ube3am-/p+ mice when they were reared normally. This developmental loss 
was prevented by DR and LOVD. 
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Supplementary Figure 2-5: Normal visual acuity in AS mice. (A) Examples of VEP 
recordings in WT mice. VEPs were evoked by presenting reversing gratings of different 
spatial frequencies. Closed circles represent amplitudes of VEPs in response to the gratings at 
maximal contrast. The open circle indicates the amplitude of noise measured at 0% contrast. 
VEP amplitudes decrease with increasing spatial frequency of stimulus indicated as cycles 
per degree (cpd). Scale bars: 50 μV, 50 msec. (B) Same as a, except that recordings were 
conducted in Ube3am-/p+ mice. (C) Averaged VEP amplitudes as a function of spatial 
frequency in WT (n = 15 mice) and Ube3am-/p+ mice (n = 13 mice). No statistically 
significant differences were found between WT and Ube3am-/p+ mice (p > 0.05, two-way 
repeated measures ANOVA).  
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Supplementary Table 2-1: Passive membrane properties of layer 2/3 pyramidal neurons 
in which mEPSC’s are recorded. Resting membrane potential (Vm), input resistance (Ri), 
Membrane capacitance (Cm), and Membrane time constant (Tau) were measured using 
Mutliclamp (Axon instruments) while cells are voltage-clamped at -70 mV. Significant 
differences were found in membrane capacitance between the two genotypes of normally 
reared young and adult mice, and in input resistance of normally reared young mice. These 
differences may indicate smaller cell size of Ube3am-/p+ mice. 
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Supplementary Table 2-2: Raw values for data presented in manuscript figures 2-1 
through 2-6. For statistical analyses, unpaired student t-tests were used unless noted. 
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Supplementary Table 2-2 (con’t): Raw values for data presented in manuscript figures 
2-1 through 2-6.  
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CHAPTER 3 
 
3. Enhanced sensory potentiation in Angelman syndrome mice 
is abolished by Ube3a expression in inhibitory neurons 
 
3.1. Overview 
Sensory experience guides development of neocortical circuits.  This activity-
dependent circuit maturation is required for normal sensory and cognitive abilities, which are 
distorted in neurodevelopmental disorders.  Here we have tested whether experience-
dependent cortical modifications require Ube3a, an E3 ubiquitin ligase whose dysregulation 
has been implicated in both autism and Angelman syndrome (AS).  Using the visual cortex as 
a model system for neocortical plasticity, we have previously found that the genetic deletion 
of UBE3A causes deficits in critical period ocular dominance plasticity, an in vivo assay for 
experience-dependent synaptic weakening.  Because visual cortical slices from Ube3a-
deficient mice exhibit deficits in activity-dependent synaptic strengthening, we hypothesized 
that the absence of Ube3a might also disrupt experience-driven forms of synaptic 
strengthening in vivo.  Using chronic recordings of visual evoked potentials (VEPs), we have 
found that repeated stimulation of phase-reversing visual stimuli produces a strong 
potentiation of synaptic responses, consistent with previous studies (Frenkel et al., 2006; 
Cooke and Bear, 2010). Contrary to our hypothesis, we observed developmentally enhanced 
potentiation of VEPs, including increased power of spontaneous local field potentials (LFP) 
in AS mice.  WT and AS mice achieved similar increases in VEP amplitude with a longer 
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period of visual stimulation, indicating the threshold for potentiation was lower in AS mice.  
Augmented plasticity and increased spontaneous LFP power were absent from mice 
maternally expressing Ube3a in inhibitory neurons alone.  Our results suggest that sensory 
experience-dependent cortical potentiation is enhanced in adult AS mice due to reduced 
inhibition.  
3.2. Introduction 
Angelman syndrome (AS) is a neurodevelopmental disorder afflicting 1 in 12,000 
individuals, characterized by profound cognitive disability, absent speech, impaired motor 
coordination, epilepsy and frequent laughter (Steffenburg et al., 1996; Clayton-Smith and 
Laan, 2003; Williams et al., 2006; Williams et al., 2010).  The genetic basis of AS is 
disruption of maternally inherited Ube3a expression on chromosome 15q11-13 (Fang et al., 
1999; Ohta et al., 1999; Robinson et al., 2000; Williams et al., 2010).  UBE3A encodes an E3 
ubiquitin ligase that recognizes and catalyzes the transfer of ubiquitin to its substrates for 
targeted proteasomal degradation.   
Despite the important role of Ube3a in the central nervous system, it remains unclear 
how its loss of expression disrupts cognitive function in AS.  Some learning deficits observed 
in clinical AS have been recapitulated in maternal-deficient Ube3a mice.  AS mice exhibit 
deficits in hippocampal-dependent learning and memory paradigms (Jiang et al., 1998; Miura 
et al., 2002; van Woerden et al., 2007).  Electrophysiology experiments carried out in the 
CA1 Schaffer collateral synapses of the hippocampus have found an increased threshold for 
long-term potentiation (LTP), the long-believed cellular mechanism that mediates memory 
(Weeber et al., 2003).  Neocortical plasticity is disrupted as well, with higher induction 
thresholds for both LTP and long-term depression (LTD) of layer IV to II/III synapses in 
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visual cortical slices (Yashiro et al., 2009).  These mechanisms are essential for experience-
dependent circuit remodeling of the cortex (Feldman et al., 1999; Malenka and Bear, 2004), 
demonstrated by blunted LTD-dependent ocular dominance plasticity during the critical 
period of AS mice (Yashiro et al., 2009; Sato and Stryker, 2010).  Although we have 
previously shown that activity-dependent synaptic weakening is impaired, it remains to be 
seen if experience driven synaptic strengthening is also impaired. 
The present study revisits the visual cortex as a model for cortical development, in 
order to determine if loss of Ube3a impacts sensory experience’s ability to strengthen 
synapses in vivo.  Using a robust LTP-dependent phenomenon in the primary visual cortex 
known as stimulus-specific response potentiation (Frenkel et al., 2006; Cooke and Bear, 
2010, 2012), we chronically recorded visual evoked potentials (VEP) in awake, head-fixed 
mice.  To our surprise we found that experience-induced augmentation of VEPs was greater, 
and the threshold for potentiation lower, in Ube3a-deficient mice.  This correlated 
developmentally with a generalized increase in spontaneous local field potential activity.  
Maternal expression of Ube3a in inhibitory neurons alone was sufficient to preclude both 
electrophysiological abnormalities.  
3.3. Results 
Normal sensory-driven potentiation in juvenile Angelman syndrome mice.  Our 
previous report, detailing impaired LTP-induction of visual cortical field potentials by tetanic 
stimulation, suggests the possibility that LTP-induction by natural sensory stimulation may 
be afflicted as well.  To test this hypothesis we bilaterally recorded local field potentials from 
layer IV in primary visual cortex, in awake, head-fixed mice.  VEPs were generated by full-
field phase reversing sinusoidal gratings fixed at 100% contrast.  The grated sinusoidal bars 
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varied in width (0.05–0.95 cpd, in 0.1 cpd increments).  Presentation of the widest bars (0.05 
cpd) triggered the largest VEP responses while the finest bars (0.95 cpds) failed to exert 
responses discernible from noise (gray screen response).  We began recording VEPs at 
postnatal day 28 (P28), an age when impaired LTP/LTD had previously been observed in 
vitro in AS model mice (Yashiro et al., 2009).   
Eleven days of daily visual stimulation incrementally boosted VEP responses (Figure 
3-1A1 and Supplemental Figure 3-1A) to similar extents in both wild-type (WT) and AS 
model (Ube3am-/p+) mice (Figure 3-1A2), indicating that experience-dependent plasticity was 
intact.  On day twelve, the now familiar stimulus (Xº) was rotated (Xº + 90º). The new 
orthogonal stimulus evoked smaller VEPs, equivalent to those on day one (Figure 3-1A3, p > 
0.05), demonstrating that the exhibited potentiation in both genotypes was entirely exclusive 
to the familiar stimulus (Xº). By the fourth day of the novel stimulus (Xº + 90º), the VEP 
response had surpassed that of the familiar stimulus (90º), and continued to increase on the 
subsequent days (Supplemental Figure 3-1A).  This suggests that the rate of potentiation to 
the novel stimulus had been enhanced by the previous experience with the familiar stimulus 
(Xº).  To assess the stability of the potentiated visual response, mice were left in their home 
cages for 7 weeks (until P100) following the eleventh day of stimulus Xº + 90º.  Upon 
reevaluation of stimulus Xº + 90º at P100, the VEP amplitude had remained elevated, and did 
not increase with further days of stimulation, confirming the response was still saturated 
(Supplemental Figure 3-2). These results imply that experience-dependent strengthening, 
specificity and stability of the circuit are functioning normally in juvenile Ube3am-/p+ mice. 
Threshold for potentiation is lower in adult Angelman Syndrome mice.  Because 
our previous data had shown that the LTP-induction threshold was even more severe at P100 
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(Yashiro et al., 2009), we were interested to see if SRP was altered in adult Ube3am-/p+ mice.  
Using the same experimental protocol applied at P28 revealed that by P100 sensory-driven 
VEP potentiation was markedly larger in Ube3am-/p+ mice, and significantly larger at P300 
relative to WT mice (Figure 3-1A2, Supplemental Figure 3-1B and 3-1C).  Interestingly, in 
adult mice (P100 and P300) the novel stimulus Xº + 90º (day 12), generated a significantly 
greater VEP response than stimulus Xº on day 1 (Figure 3-1A3).  Although this robust form 
of perceptual learning persists into late-adulthood, it may be less stimulus-selective.   
To further understand the enhanced SRP in adult Ube3am-/p+ mice, we examined how 
quantity of visual stimulation influenced the magnitude of potentiation.  Animals were either 
briefly or heavily stimulated daily, with 100 or 1100 phase reversals respectively, at 1 Hz and 
0.05 cpd (Figure 3-1B1 and Supplemental Figure 3-3).  Visual responses developed to a 
greater extent in Ube3am-/p+ mice compared to WTs when daily stimulation was brief (Figure 
3-1B2).  However, 1100 phase reversals elicited a similar degree of potentiation in WT and 
Ube3am-/p+ mice.  While the longer period of stimulation had a greater effect on WT VEP 
responses, Ube3am-/p+ mice responded similarly to both 100 and 1100 phase reversals, 
implying the visual response had been saturated by 100 phase reversals.  Brief stimulation 
also only led to SRP that was entirely stimulus-specific in WT mice (Figure 3-1B3).  
Complete specificity was absent in both genotypes following 1100 phase reversals. 
Power of spontaneous local field potentials increases developmentally in Angelman 
syndrome mice.  We recorded spontaneous local field potential (LFP) activity to assess the 
state of the visual cortical network, because sensory evoked activity may be influenced by 
ongoing cortical activity (Arieli et al., 1995; Arieli et al., 1996; Fellinger et al., 2011).  The 
fast-fourier transform (FFT) function was used for spectral analysis of LFPs, recorded from 
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the same microelectrodes used in VEP recordings, prior to the outset of the visual plasticity 
paradigm.  Power spectral analysis revealed that spontaneous visual cortical activity was 
depressed in the alpha, beta and gamma bands of juvenile (P28) Ube3am-/p+ mice (Figure 3-
2A).  However, as Ube3am-/p+ mice matured, the level of spontaneous activity rose across all 
frequency bands relative to WT mice (Figure 3-2B and 3-2C).  Activity within the delta, 
theta and alpha frequency bands was significantly greater in Ube3am-/p+ mice at both P100 
and P300, and no longer attenuated in the beta-gamma range. 
Augmented LFP activity and plasticity absent in mice expressing Ube3a in 
inhibitory neurons.  Several recent studies have found evidence for a developmental loss of 
inhibition in Ube3a-deficient mice that parallels the increase in spontaneous LFP activity and 
plasticity that we have identified (Egawa et al., 2012; Wallace et al., 2012).  Considering that 
reduced inhibition may lead to overall increased excitation, possibly elevating spontaneous 
LFP activity and plasticity, we investigated the effect of maternal expression of Ube3a in 
inhibitory neurons.  Ube3a expression was limited to inhibitory neurons by crossing GAD2-
CRE transgenic and Ube3a-loxP-STOP-loxP mice (GAD2-CRE:Ube3astop/+).   
Immunofluorescence studies were carried out with anti-Ube3a and anti-GABA to 
confirm Ube3a recombination was restricted to inhibitory neurons (Figure 3-3A).  FFT 
analysis was performed on spontaneous LFP activity within the primary visual cortex of 
adult (P100) GAD2-CRE:Ube3astop/+ mice.  Delta activity was significantly lower in GAD2-
CRE:Ube3astop/+ mice relative to WTs, however power at higher frequency bands (theta, 
alpha, beta, and gamma) was normal (Figure 3-3B).  When sensory experience-dependent 
plasticity was tested, we found that the magnitude and stimulus-specificity of potentiation 
was equivalent in WT and GAD2-CRE:Ube3astop/+ mice (Figure 3-3C).  Repeated 
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presentation of stimulus Xº + 90º (days 12-22) conversely, failed to increase VEP amplitude 
in GAD2-CRE:Ube3astop/+ mice to the same extent as in WT mice (Supplementary Figure 3-
4).  
3.4. Discussion 
Disruption of memory and plasticity has been an area of great interest in Angelman 
syndrome (AS) research over the past 15 years.  Numerous studies have described attenuated 
LTP of electrically evoked field potentials in Ube3am-/p+ mice, both within CA1 
hippocampus and the primary visual cortex (Jiang et al., 1998; Miura et al., 2002; Weeber et 
al., 2003; van Woerden et al., 2007; Yashiro et al., 2009; Sato and Stryker, 2010; Baudry et 
al., 2012; Kaphzan et al., 2012).  This study is the first to provide evidence of an augmented 
form of synaptic plasticity in AS, known as stimulus-specific response potentiation (SRP).  
SRP is an experience-dependent enhancement, in part, of the thalamocortical synapses in the 
primary visual cortex.  This enhancement is manifested by an increase in the visual evoked 
potential (VEP) response, and has many of the attributes of conical LTP.  It is long lasting, 
can be prevented by either blocking NMDA receptors or inhibiting AMPA receptor insertion, 
and its maintenance is abolished by inhibition of PKMζ, a kinase that maintains NMDA-
dependent LTP (Frenkel et al., 2006; Cooke and Bear, 2010).  These properties suggests that 
this type of endogenous plasticity is a naturally occurring form of thalamacortical LTP. 
When we examined the SRP phenomenon in juvenile AS model mice no deficits were 
found.  The rate and magnitude of VEP potentiation was indistinguishable from WT mice, 
and very stable.  There was no sign of decline in the potentiated response even after 7 weeks 
without visual stimulation.  Speculating that the increase in LTP-induction threshold, 
observed in vitro at P25, might be too small to influence SRP, we examined adult Ube3am-/p+ 
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mice reported to have more severely impaired LTP (Yashiro et al., 2009).  However, by P100 
Ube3am-/p+ mice were exhibiting a greater gain in VEP responses from day-to-day 
stimulation, than were WT mice.  The magnitude of this gain appeared to have fully matured 
by P100 and persisted into late-adulthood (P300).  SRP potentiation was the same in adult 
AS mice whether being stimulated daily with 100 or 1100 phase reversals.  On the other 
hand, WT mice showed greater potentiation with 1100 phase reversals, equivalent to Ube3am-
/p+ mice.  This suggests that Ube3am-/p+ mice may in fact have a lower threshold for this form 
of experience-dependent plasticity.  This is surprising because in slice Ube3am-/p+ mice have 
a higher LTP-induction threshold for layer IV to II/III synapses in the primary visual cortex 
(Yashiro et al., 2009). 
Emergence of the VEP enhancement in Ube3am-/p+ mice corresponds with a general 
increase of spontaneous local field potential (LFP) activity.  Young Ube3a-deficient mice 
have a reduction of power across the alpha, beta and gamma bands. By adulthood that 
reduction is gone, replaced by increased power in the delta, theta and alpha bands.  While 
oscillations in narrow frequency bands of LFP activity correspond to a wide variety of 
behavioral and cognitive states (Basar et al., 2001; Kahana, 2006), less is known about the 
significance of broadband shifts in activity such as those observed in the Ube3am-/p+ mice.  
Increases in broadband LFP activity have been shown to correspond to increased neuronal 
spiking (Manning et al., 2009; Miller, 2010).  This leads us to speculate that the lower 
broadband power observed in young Ube3am-/p+ mice may be due to reduced population 
spiking, which transitions into an overactive state in adulthood.  An important test will be to 
see if single-unit recordings confirms this, and to determine the relative contributions of 
inhibitory/excitatory neuronal spiking.  This plays into evidence of an excitatory/inhibitory 
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imbalance in AS, where reduced cortical excitation in juvenile Ube3am-/p+ mice (Yashiro et 
al., 2009), is reversed by an aggregative loss of inhibition observed both in the cerebellum 
and cortex (Egawa et al., 2012; Wallace et al., 2012).   
To determine whether inhibitory decline, due to loss of Ube3a, was impacting the 
SRP enhancement, we utilized CRE recombinant mice that expressed maternal Ube3a 
exclusively under the GAD65 promoter, a marker for inhibitory neurons.  Indeed, limiting 
Ube3a expression to inhibitory neurons was sufficient in preventing an exaggerated 
experience-dependent VEP response.  Restoration of Ube3a in inhibitory neurons also 
eliminated elevated broadband LFP activity.  There was a curious decrease of delta power in 
the GAD2-CRE:Ube3astop/+ mice which may reflect a complex interplay between inhibitory 
and dysfunctional Ube3a-deficient excitatory neurons. 
Our findings fit the growing literature of evidence for an increased excitation to 
inhibition ratio in autism (Rubenstein and Merzenich, 2003; Bourgeron, 2009; Yizhar et al., 
2011). Fragile X syndrome (Fmr1 KO) mice exhibit cortical hyperexcitability due to 
decreased excitatory drive onto inhibitory neurons (Gibson et al., 2008).  Excitatory drive 
onto inhibitory neurons is normal is AS model, however the reciprocal drive of inhibitory 
synapses onto excitatory neurons is developmentally reduced in the cortex (Wallace et al., 
2012).  Network dynamics in AS are further complicated because excitatory 
neurotransmission is also substantially reduced, leading to a cortical LTP deficit, at least in 
vitro (Yashiro et al., 2009).  It appears that the net balance of excitation/inhibition in adult 
AS may be in favor of reduced inhibition.  The reduction of inhibitory tone by the disruption 
of GABA synthesis has been shown to increase experience-dependent OD plasticity in the 
visual cortex of adult rats (Harauzov et al., 2010).  This rise in adult plasticity is 
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accompanied by improved synaptic strengthening, but not synaptic weakening, suggesting 
the OD shift may have occurred because of enhanced open eye potentiation.  SRP may 
similarly be enhanced in AS mice due to a net increase excitation, which is not present when 
Ube3a expression is limited to inhibitory cells.  One of the consequences of the hyper-plastic 
adult Ube3am-/p+ mice was a lower threshold for nonspecific VEP potentiation evoked by a 
novel visual stimulus.  These modifications to experience-dependent plasticity may underlie 
some of the sensory processing disturbances reported in AS (Walz and Baranek, 2006).  
Treatment with the administration of a GABAergic agonist has been effecting in restoring 
inhibitory function in the cerebellum of AS, including ameliorating some of the motor 
deficits (Cheron et al., 2005; Egawa et al., 2012).  It would be interesting to see if 
administration of a GABAergic agonist might be equally effective in restoring normal 
experience-dependent plasticity in the adult visual cortex. 
3.5. Material and Methods 
Animals 
Male and female C57BL6/J WT and maternally deficient Ube3a mice were generated 
by crossing paternally deficient Ube3a females with WT males. Juvenile, adult and late adult 
mice ranged from P27-29, P90-120, P255-310 respectively.   Mice were kept on a 12-hour 
dark/light cycle and given ad libitum access to food and water.  All experimental animal 
procedures were carried out according to the NIH Guide for the Care and Use of Laboratory 
Animals and the Society for Neuroscience Policy on the Use of Animals in Neuroscience 
Research and were approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. 
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Transgenic male and female GAD2-Cre;lox-Stop-lox-ube3a mice were utilized to 
obtain maternal expression of Ube3a in interneurons.  Mice were on a mixed C57BL6/J 
background and ranged from P90-120.  
Surgery for in vivo recordings 
Mice were anesthetized with ketamine / xylazine (120 mg: 9 mg/kg; Bioniche Pharma 
/ AnaSed) delivered intraperitoneally, and 0.25 % bupivacaine (Hospira) was locally applied 
to the scalp incision site.  Sharpened tungsten microelectrodes (0.3-0.5 MΩ impedance 
range; FHC) were bilaterally implanted into the binocular zone of V1, ±3.00 mm lateral of 
lamda and -0.45 mm ventral from brain surface.  Silver reference electrodes were implanted 
±2.00 mm lateral and -1.0 mm posterior of bregma, on the brain surface.  A head-restraint 
holding post was placed on the skull surface, anterior to the reference electrodes, and all were 
secured to the skull with cyanoacrylic (Henkel).  Mice were given at least 48 h to recover 
before being habituated to the head-restraint apparatus for 45 min.   
EEG recordings 
EEG recordings were taken 24 hr after the initial habituation to the head-restraint, in 
the absence of visual stimulation.  The first 10 min of recording were discarded (habituation 
period) and the following 25 min utilized for EEG analysis.  All recordings were amplified 
1000x, and high and low band filters set to 0.1 Hz and 100 Hz respectively (Grass 
Technologies).  Data were acquired and digitized at 4096 Hz into Spike2 (Cambridge 
Electronic Design).   Spectral analysis was performed using a Fast Fourier Transform (FFT 
size 8192; Hanning Window), and grouped into the following EEG bands: delta (1-3.5 Hz), 
theta (4-7.5 Hz), alpha (8-12 Hz), beta (13-20 Hz) and gamma (21-50 Hz). 
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Visual Evoked Potentials (VEP) 
VEPs were recorded 24 hr after EEG recordings (48 hr after head-restraint 
habituation).  Mice were placed 20 cm from a 21 inch CRT computer monitor (80 cd/m2) and 
visually stimulated with 1 Hz square-wave reversing sinusoidal gratings oriented at either 0º 
or 90º (Vision Research Graphics).  Visual stimuli were presented in groups of 34 
consecutive reversals followed by a 10 sec break (black screen).  VEP responses were 
calculated as the trough to peak amplitude of 102 averaged presentations. 
Stimulus-Selective Response Potentiation (SRP) 
To characterize SRP across development (P28, P100, P300), each mouse was 
presented with a randomized array of visual stimulation consisting of 102 presentations of 
0.05, 0.15, 0.25, 0.35, 0.45, 0.55, 0.65, 0.75, 0.85 and 0.95 cpd, including 2.84 cpd and the 
gray screen response as controls.  The array of visual stimuli were all presented in one 
orientation (0º or 90º) for 11 consecutive days.  On the 12th day the grating orientation was 
rotated 90º and maintained for another 10 consecutive days until the 23rd day when the 
orientation was reverted back to the starting orientation.  
To assess the effect of presentation number on SRP, mice were presented with either 
102 or 1122 grating reversals at only 0.05 cpd.  For mice receiving 1122 presentations, the 
VEP amplitude was determined from the average of the first 102 reversals.   
Histology and Immunohistochemistry 
Mice were deeply anesthetized with sodium pentobarbital (60 mg/kg i.p.) prior to 
transcardial perfusion with room temperature phosphate-buffered saline (PBS) immediately 
followed by room temperature phosphate-buffered 4% paraformaldehyde (pH 7.3).  Perfused 
brains were removed from their skulls and postfixed overnight at 4°C prior to being 
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cryoprotected via sequential 12-hour incubations in 10%, 20%, and 30% sucrose in PBS (pH 
7.5).  Cryoprotected brains were frozen on dry ice and cut into 40 m-thick sections with a 
sliding microtome (Thermo Scientific, Kalamazoo, MI, USA).  Sections were stored in a 
cryopreservative solution (by volume: 45% PBS, 30% ethylene glycol, 25% glycerol) at -
20°C until they were processed for free-floating immunohistochemistry. 
For immunofluorescent staining, sections were rinsed several times in PBS before 
blocking in PBS plus 5% normal goat serum and 0.02% Triton-X-100 (NGST) for 1 hour at 
room temperature.  Blocked tissue sections were incubated in primary antibodies (1:1000 rb 
anti-GABA, Sigma-Aldrich; 1:200 ms anti-Ube3a, Sigma-Aldrich) diluted in NGST for 48 
hours at 4°C.  Sections were then rinsed several times in PBS containing 0.02% Triton-X-
100 (PBST) before incubation in secondary antibodies (also diluted in NGST) for 1 hour at 
room temperature.  In most experiments, 4',6-diamidino-2-phenylindole (DAPI, Invitrogen 
D1306) was added during the secondary antibody incubation at a concentration of 700 ng/mL 
for nuclear counterstaining.  Images of brain sections were acquired with a Zeiss LSM 710 
confocal microscope equipped with ZEN imaging Software (Zeiss, Jena, Germany). 
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Figure 3-1:  Adult experience-dependent potentiation is enhanced in Angleman 
syndrome mice.  (A1) Visual-evoked potentials (VEP) were recorded bilaterally from layer 
IV of primary visual cortex in awake, head-fixed mice.  Animals were visually stimulated 
with phase-reversing sinusoidal gratings (Xº) for eleven consecutive days, triggering a 
gradual potentiation in the VEP amplitude.  The stimulus-selectivity of the enhanced 
response is demonstrated on the twelfth day when the now-familiar stimulus is rotated 90º 
(Xº + 90º).  Traces are representative VEP waveforms from a single WT mouse, while the 
line graph represents the average VEP amplitude of all WT mice tested at P100.  (A2) Traces 
are the average VEP waveform of all WT (blue) and Ube3am–/p+ (red) mice, on day one 
(baseline) and eleven (potentiation) of visual stimulation, among three different age groups 
(P28, P100, P300).  Juvenile (P28) Ube3am–/p+ mice exhibited a similar magnitude of 
potentiation to WTs following eleven days of visual stimulation, but was significantly 
enhanced in adulthood (p < 0.01).  (A3) Average WT and Ube3am–/p+ VEP waveform on days 
one (baseline) and twelve (potentiated).  Adult mice exhibited significantly more stimulus-
nonselective response potentiation (SNRP), absent in the juvenile mice. There were no 
genotype differences.  (B1) The average percent increase in VEP amplitude following modest 
66 
 
daily visual stimulation (100 phase reversals) at P100.  (B2) The potentiation threshold was 
significantly lower in Ube3am–/p+ mice when presented 100 phase reversals daily, but 
comparable with more rigorous stimulation (1100 phase reversals).  (B2) Presenting 100 
phase reversals daily only induced SNRP in Ube3am–/p+ mice, while SNRP was obtained in 
both genotypes with 1100 phase reversals daily.   
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Figure 3-2: Developmental rise in visual cortical EEG power in Angelman syndrome 
mice.  (A) Spontaneous EEG activity was recorded from V1, prior to visual stimulation 
paradigm.  Juvenile Ube3am–/p+ mice exhibit significantly less power in the alpha, beta and 
gamma bands.  (B) Adult (P100) Ube3am–/p+ mice reveal a general increase in power across 
all frequency bands relative to WTs, with significantly greater levels of power in delta, theta, 
alpha and beta bands.  (C) The increase in power is preserved in late adulthood (P300) in 
Ube3am–/p+ mice. 
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Figure 3-3: Increased EEG activity and enhanced potentiation is abolished by Ube3a 
expression in inhibitory neurons.  (A) Immunohistochemistry from sagittal sections 
through the visual cortex at P100.  GAD2-CRE:Ube3astop/+ mice only express Ube3a 
maternally in GABA producing inhibitory neurons.  (B) Maternal expression of Ube3a in 
inhibitory neurons led to reduced power in the delta frequency band.  (C1) Following eleven 
days of visual stimulation (C2) WT and GAD2-CRE:Ube3astop/+ mice displayed comparable 
degrees of VEP potentiation, (C3) as well as SNRP. 
   
69 
 
 
Supplemental Figure 3-1:  Developmentally enhanced VEP potentiation in Angleman 
syndrome mice.  (A) Traces represent example VEP waveforms from an individual WT 
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(blue) and Ube3am–/p+ (red) mouse over 23 days of visual stimulation.  The graphs represent 
the average VEP amplitude with the percent increase from day one in the insets. Phase 
reversing sinusoidal gratings (Xº) were presented for eleven days, resulting in a potentiated 
response. On day 12 the grating orientation was reversed (Xº + 90º), representing a novel 
stimulus, presented for an additional 11 days, and then reverted back to the original 
orientation to demonstrate retention of potentiation.  (B) There is a trend towards greater 
potentiation in adult (P100) Ube3am–/p+ mice following 11 days of visual stimulation.  The 
enhanced potentiation becomes more apparent in the Ube3am–/p+ mice on days 12-22 with 
introduction of the novel stimulus (Xº + 90º). (C) The enhanced potentiation is more 
apparent the later-adult (P300)  Ube3am–/p+ mice. 
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Supplemental Figure 3-2:  Potentiated response is maintained for 7 weeks.  (A) Traces 
are representative waveforms from an individual WT and Ube3am–/p+ mouse.  Mice visually 
stimulated for 23 days starting at P28 (subset of mice from Supplementary Figure 3-2A), 
were left in their homecages for 7 weeks until P100, and visually reevaluated.  After the 7 
week break, mice from both genotypes maintained potentiated VEP responses, which could 
not be increased any further with subsequent days of visual stimulation. 
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Supplemental Figure 3-3:  Lower threshold for potentiation in adult Angelman 
syndrome mice.  Adult (P100) mice were either stimulated with (A) 100 or (B) 1100 phase 
reversals of 0.05 cpd daily.  (A) The representative VEP waveforms are from an individual 
WT (blue) and Ube3am–/p+ (red) mouse, and line graphs signify the average of both 
genotypes.  Ube3a-deficient mice exhibited greater potentiation (days 1-11, 12-22) that was 
also less stimulus-specific (day 12), relative to WTs, when daily stimulation was brief (100 
phase reversals).  (B) However, both the magnitude and specificity of the VEP response were 
comparable between genotypes when the duration of stimulation was increased (1100 phase 
reversals).  
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Supplemental Figure 3-4:  Ube3a expression in inhibitory neurons attenuates sensory 
potentiation.  (A) WT and GAD2-CRE:Ube3astop/+ mice displayed comparable degrees of 
VEP potentiation to stimulus Xº (day 1-11).  Presentation of the novel stimulus Xº + 90º (day 
12-22) to GAD2-CRE:Ube3astop/+ mice, failed to raise VEP responses to the same extent as 
WT mice.  Blue (WT) and green (GAD2-CRE:Ube3astop/+) line graphs represent the average 
VEP responses for each group.  Shaded regions denote S.E.M. 
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CHAPTER 4 
 
4. Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome2 
4.1. Overview 
Angelman syndrome (AS) is a neurodevelopmental disorder caused by maternal 
deletions or mutations of the ubiquitin ligase E3A (UBE3A) allele and characterized by 
minimal verbal communication, seizures, and disorders of voluntary movement. Previous 
studies have suggested that abnormal dopamine neurotransmission may underlie some of 
these deficits, but no effective treatment currently exists for the core features of AS. A 
clinical trial of levodopa (L-DOPA) in AS is ongoing, although the underlying rationale for 
this treatment strategy has not yet been thoroughly examined in preclinical models. We found 
that AS model mice lacking maternal Ube3a (Ube3am–/p+ mice) exhibit behavioral deficits 
that correlated with abnormal dopamine signaling. These deficits were not due to loss of 
dopaminergic neurons or impaired dopamine synthesis. Unexpectedly, Ube3am–/p+ mice 
exhibited increased dopamine release in the mesolimbic pathway while also exhibiting a 
decrease in dopamine release in the nigrostriatal pathway, as measured with fast-scan cyclic 
voltammetry. These findings demonstrate the complex effects of UBE3A loss on dopamine 
                                                            
2 Riday, T.T., Dankoski, E.C., Krouse, M.C., Fish, E.W., Walsh, P.L., Han, J.E., Hodge, C.W., Wightman, 
R.M., Philpot, B.D., and Malanga, C.J. (2012). Pathway‐specific dopaminergic deficits in a mouse 
model of Angelman syndrome. The Journal of clinical investigation 122, 4544‐4554. 
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signaling in subcortical motor pathways that may inform ongoing clinical trials of L-DOPA 
therapy in patients with AS. 
4.2. Introduction 
Angelman syndrome (AS) is a neurodevelopmental disorder characterized by 
intellectual disability, profound language impairment, seizures, and a propensity for a happy 
disposition (Steffenburg et al., 1996; Peters et al., 2004; Williams et al., 2006). AS results 
from loss of function of the maternally inherited UBE3A allele at the 15q11-q13 locus (Knoll 
et al., 1989; Williams et al., 1990; Kishino et al., 1997a; Rougeulle et al., 1997; Vu and 
Hoffman, 1997; Mabb et al., 2011). The UBE3A gene encodes a HECT domain E3 ubiquitin 
ligase (UBE3A, also known as E6AP) involved in protein degradation through the ubiquitin-
proteasome pathway (Kishino et al., 1997a; Sutcliffe et al., 1997a). Clinical treatment of AS 
commonly includes pharmacotherapy for seizures, problem behaviors, and motor dysfunction 
(Pelc et al., 2008). Although treatments for AS are limited, a case study of 2 adults with AS 
found that levodopa (L-DOPA) administration dramatically improved resting tremor and 
rigidity (Harbord, 2001), leading to a clinical trial of L-DOPA in individuals with AS (Tan, 
2012).  
There are few published studies validating the rationale for using L-DOPA to treat 
parkinsonian features in AS. AS model mice lacking maternal Ube3a (Ube3am–/p+ mice) were 
reported to have reduced dopamine cell number in the substantia nigra pars compacta (SNc) 
by 7 to 8 months of age (Mulherkar and Jana, 2010). In Drosophila, UBE3A has been shown 
to regulate GTP cyclohydrolase I, an essential enzyme in dopamine biosynthesis (Ferdousy et 
al., 2011). However, little is known about the function of mesolimbic or nigrostriatal 
dopamine pathways in AS, which have vital roles in several of the behaviors or motor 
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symptoms commonly managed with pharmacotherapy, including hyperactivity, impulsivity, 
tremor, and rigidity. A survey of psychoactive drugs used in patients with AS reported that 
the majority responded poorly to stimulant medications (Philpot et al., 2011), most of which 
act by increasing available extracellular dopamine levels.  
We examined dopamine-dependent behaviors as well as dopamine synthesis, content, 
and release in the mesolimbic and nigrostriatal pathways of AS model mice. Ube3am–/p+ mice 
were more sensitive to brain stimulation reward (BSR) but less sensitive to the effects of 
drugs that increase extracellular dopamine in behavioral measures of both reward and 
locomotion. Surprisingly, we found increased dopamine release in the mesolimbic system but 
decreased release in the nigrostriatal system. These changes in dopaminergic function were 
not accounted for by differences in dopaminergic cell number or differences in tyrosine 
hydroxylase levels or dopamine content in the terminal fields of the nucleus accumbens 
(NAc) or dorsal striatum. Our findings raise the possibility that similar effects on 
dopaminergic systems may occur in humans and may inform ongoing and future clinical 
trials of L-DOPA in individuals with AS. 
4.3. Results 
Ube3am–/p+ mice are more sensitive to rewarding electrical brain stimulation. 
Activity of mesolimbic dopaminergic neurons in the midbrain ventral tegmental area (VTA) 
is critical for the perception of reward (Cooper and Breese, 1975; Wise, 2002). To determine 
whether loss of UBE3A alters mesolimbic dopamine function, Ube3am–/p+ and WT mice 
were implanted with stimulating electrodes in the medial forebrain bundle (MFB) and trained 
to perform operant intracranial self-stimulation (ICSS) by turning a wheel (Supplemental 
Figure 1A). Thresholds for perception of BSR were determined before and after 
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administration of drugs that increase extracellular dopamine levels (Figure 4-1A). Ube3am–/p+ 
mice showed a leftward shift of the baseline charge-response curve (Figure 4-1B), indicating 
that these mice required less charge than WT littermates to sustain the same degree of wheel 
turning (Figure 4-1C; U = 59.0, P < 0.001). There was no difference in the maximum rate of 
operant responding between genotypes (Figure 4-1D), demonstrating that voluntary motor 
function required for ICSS was unimpaired in Ube3am–/p+ mice. Ube3am–/p+ mice also 
sustained a lower reward threshold for longer than WT littermates (16–30 minutes, P < 
0.001; 31–45 minutes, P < 0.001; 46–60 minutes, P = 0.026; Figure 4-1E). 
Ube3am–/p+ mice are less sensitive to dopaminergic manipulation of BSR. Drugs that 
enhance extracellular dopamine availability increase the potency of BSR, measured as a 
lowered BSR threshold (Supplemental Figure 4-1, B and C). To determine whether the 
increase in reward sensitivity in Ube3am–/p+ mice was due to changes in dopamine 
neurotransmission, we investigated the effects of pharmacological manipulation on BSR 
threshold. The nonselective monoamine reuptake blocker, cocaine, similarly lowered BSR 
thresholds in both genotypes at the peak of its effect from 0 to 15 minutes after i.p. 
administration (Figure 4-2, A and B, and Supplemental Figure 4-2A), but the reward-
potentiating effects of cocaine decayed more slowly in Ube3am–/p+ mice (Figure 4-2C). 
Maximum operant response rates showed a greater increase following cocaine administration 
in WT mice at 10.0 mg/kg cocaine (31–45 minutes, P = 0.028) and 17.0 mg/kg cocaine (31–
45 minutes, P = 0.001; Supplemental Figure 4-3A), indicating that cocaine effects on operant 
motor behavior are reduced in Ube3am–/p+ mice. The highly selective dopamine transporter 
(DAT) blocker GBR 12909 reduced reward threshold similarly to cocaine but remained 
active for over 2 hours following administration. GBR 12909 lowered reward threshold 
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significantly less in Ube3am–/p+ mice, revealing a more pronounced difference in potentiation 
of BSR than that seen with cocaine (10.0 mg/kg, P = 0.002; 17.0 mg/kg, P < 0.001; Figure 4-
1F and Supplemental Figure 2B). The ability of GBR 12909 to increase the maximum 
operant response rate was also reduced in Ube3am–/p+ mice at 10.0 mg/kg (76–90 minutes, P 
= 0.032; 91–105 minutes, P = 0.018) and 17.0 mg/kg (76–90 minutes, P = 0.015; 91–105 
minutes, P = 0.004; Supplemental Figure 4-3B). 
To assess possible differences in dopamine receptor sensitivity in the NAc and other 
forebrain targets, we measured the potency of selective dopamine receptor antagonists in 
reducing BSR. We found that the D1 receptor antagonist SCH 23390 elevated BSR 
thresholds similarly in both genotypes (Figure 4-2D and Supplemental Figure 4-2C). The 
motor depressant effect of SCH 23390 on maximum operant response rate was also similar 
between WT and Ube3am–/p+ mice (Figure 4-2G and Supplemental Figure 4-3C), suggesting 
that dopamine acting through D1 receptors was unaffected by loss of UBE3A. The reward 
threshold-elevating effects of the D2/3 receptor antagonist raclopride (Figure 4-2E) and D2-
selective receptor antagonist L741,626 (Figure 4-2F) were also similar between genotypes 
(see also Supplemental Figure 4-2, D and E). However, the depressant effect of both 
raclopride (16–30 minutes, 0.178 mg/kg, P = 0.005; 0.3 mg/kg, P < 0.001; Figure 4-2H and 
Supplemental Figure 4-3D) and L741,626 (46–60 minutes, 5.6 mg/kg, P < 0.001; Figure 4-2I 
and Supplemental Figure 4-3E) on maximum operant response rate was blunted in Ube3am–
/p+ mice.  
Ube3am–/p+ mice are less sensitive to cocaine-stimulated locomotor activity. To 
further assess dopamine-related behavior in Ube3am–/p+ mice, we performed locomotor 
sensitization experiments using cocaine (5.6, 10.0, or 17.0 mg/kg i.p.) as a tool to evaluate 
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both acute locomotor stimulation and adaptation to repeated drug exposure (Figure 4-3). 
Cocaine has a rapid onset of action, with brain concentrations peaking approximately 5 
minutes after injection, and a half-life of approximately 15 minutes (Benuck et al., 1987). 
Therefore, we used the total activity in the first 15 minutes following injection to compare 
cocaine-stimulated locomotor activity between genotypes. Total locomotion over the 15 
minutes following saline injection was lower in Ube3am–/p+ mice (531 ± 51 cm) than in WT 
mice (916 ± 79 cm; U = 266, P < 0.001), consistent with decreased motor activity previously 
described in Ube3am–/p+ mice (Allensworth et al., 2011). Although a low cocaine dose (5.6 
mg/kg; Figure 4-3A) was sufficient in both genotypes to induce locomotor sensitization, 
defined as greater distance traveled on the challenge/last day compared with that on the first 
day of administration (P < 0.001), we found Ube3am–/p+ mice to be less sensitized than WT 
mice (day 4, P = 0.02; day 5, P = 0.031; challenge, P = 0.031; Figure 4-3D). An intermediate 
cocaine dose (10.0 mg/kg; Figure 4-3B) increased locomotion more in WT mice than in 
Ube3am–/p+ mice for 5 consecutive days after the first day of exposure (day 2, P = 0.009; day 
3, P = 0.012; days 4–6, P < 0.001), although this difference was no longer significant on 
cocaine challenge after 7 days (Figure 4-3E). The largest cocaine dose tested (17.0 mg/kg; 
Figure 4-3, C and F) stimulated comparable locomotion on the second day of exposure in 
both genotypes, suggesting that the reduced cocaine effect in Ube3am–/p+ mice was not due to 
a reduction in maximum cocaine potency or a ceiling effect.  
Neuroanatomical and biochemical markers of dopamine are unaltered in Ube3am–
/p+ mice. Projection neurons within the VTA and SNc express both UBE3A and tyrosine 
hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis. We performed 
immunohistochemistry to confirm maternal imprinting of Ube3a in the VTA and SNc 
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(Figure 4-4A) and then quantified TH-positive neurons with design-based stereology in the 
VTA and SNc. We found no differences in the estimated dopamine cell number in either 
region at P100 (Table 4-1 and Figure 4-4B). We performed Western blots for TH in the NAc 
and dorsal striatum as a measure of biosynthetic capacity in dopaminergic terminal fields 
originating from neurons in the VTA or SNc, respectively. TH protein levels were similar 
between Ube3am–/p+ and WT mice in the NAc and striatum (Table 4-2 and Figure 4-4C). 
HPLC on tissue homogenates showed no difference in total dopamine content in Ube3am–/p+ 
mice in the NAc or dorsal striatum (Table 4-2 and Figure 4-4D). Furthermore, tissue 
concentrations of DOPAC, the primary acid metabolite of dopamine (Figure 4-4E), and 
dopamine/DOPAC concentration ratios (Figure 4-4F) were comparable between genotypes. 
Dopamine transmission is enhanced in the NAc and reduced in the dorsal striatum 
of Ube3am–/p+ mice. We performed fast-scan cyclic voltammetry (FSCV) in the NAc and 
dorsal striatum to determine whether the loss of UBE3A affected phasic dopamine 
transmission in these limbic and motor terminal regions, respectively (Figure 4-5). 
Stimulation of the MFB resulted in greater dopamine release in the NAc of Ube3am–/p+ mice 
across all stimulus frequencies (Figure 4-5A and Supplemental Figure 4-4A), with higher 
maximum extracellular dopamine concentrations obtained at 30 to 60 Hz (30 Hz, P = 0.05; 
40 Hz, P = 0.008; 50 Hz, P = 0.045; 60 Hz, P = 0.004; Figure 4-5, C, E, and G). In contrast 
to that in the NAc, we found reduced dopamine release across all stimulus frequencies 
(Figure 4-5B and Supplemental Figure 4-4B), with lower maximum extracellular dopamine 
concentration in the dorsal striatum of Ube3am–/p+ mice at 30 to 50 Hz (30 Hz, P = 0.006; 40 
Hz, P = 0.002; 50 Hz, P = 0.015; Figure 4-5, D, F, and H). Modeling of the FSCV data did 
not reveal any differences in dopamine uptake following stimulation in either the NAc or 
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dorsal striatum (data not shown). Administration of the DAT blocker GBR 12909 prior to 
stimulation caused similar changes to the time course of extracellular dopamine 
concentrations in the NAc and dorsal striatum (Figure 4-5, I and J), suggesting no differences 
in dopamine reuptake between genotypes. 
4.4. Discussion 
The principal findings of this study are that Ube3am–/p+ mice, a model of AS, exhibit 
increased mesolimbic dopamine release but decreased nigrostriatal dopamine release and 
decreased behavioral sensitivity to drugs that enhance extracellular dopamine availability. 
Release of accumbal dopamine is critical to the rewarding effects associated with both BSR 
and drugs of abuse as well as natural incentives such as food and sex (Wise and Rompre, 
1989). We used ICSS as an experimental model to directly assess motivation and reward and 
to minimize effects from potential sensory processing abnormalities (Wise, 2002; Walz and 
Baranek, 2006). We found that Ube3am–/p+ mice required significantly less electrical 
stimulation to attain the same level of responding for BSR as in controls and were able to 
maintain a higher degree of responding for BSR over time, consistent with the increased 
dopamine release in the NAc following MFB stimulation that we observed with FSCV. 
Increased extracellular dopamine could result from slower dopamine uptake, but no 
differences in accumbal dopamine clearance were observed with FSCV by either modeling of 
uptake kinetics or by administration of GBR 12909, a selective DAT blocker. This suggests 
that the increase in extracellular dopamine in the NAc is the result of increased release. 
However, Ube3am–/p+ mice were also less sensitive to the reward-potentiating effects of the 
DAT-selective reuptake blocker GBR 12909 on BSR. While this suggests that loss of 
UBE3A may affect dopamine receptor signaling in the NAc, the attenuated response could 
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not be accounted for by differences in D1 or D2 receptor activity, since antagonism of both 
receptors elevated reward thresholds equally in both genotypes.  
In contrast to that in the NAc, electrically stimulated extracellular dopamine was 
significantly reduced in the dorsal striatum of Ube3am–/p+ mice. As in that in the NAc, we 
observed no differences in striatal dopamine clearance with FSCV by either modeling of 
uptake kinetics or by administration of GBR 12909, indicating normal DAT function. This 
suggests that extracellular levels of dopamine are lower in dorsal striatum as a result of 
reduced release. One of the primary local regulators of dopamine release is negative feedback 
through D2 autoreceptors on dopaminergic terminals. Although D2 antagonism did not 
differentially affect BSR threshold in Ube3am–/p+ mice, the inhibitory potencies of both the 
D2/D3 antagonist raclopride and the D2-selective antagonist L741,626 in reducing maximum 
operant response rate were significantly lower, suggesting decreased D2 receptor function. 
Mice lacking D2 receptors exhibit some similarities to Ube3am–/p+ mice, including decreased 
cocaine-stimulated locomotion (Chausmer et al., 2002; Welter et al., 2007) and increased 
extracellular dopamine in the NAc following MFB stimulation (Rouge-Pont et al., 2002), the 
latter effect due to decreased D2 autoreceptor function (Bello et al., 2011). However, in 
contrast to Ube3am–/p+ mice, D2-deficient mice are also less sensitive to BSR alone (Elmer et 
al., 2005), suggesting that the increased sensitivity to BSR and the changes in dopamine 
release in the NAc and dorsal striatum that we observed in Ube3am–/p+ mice may be due to 
alterations in other signaling pathways not yet investigated.  
Interestingly, some of the changes that we observed in Ube3am–/p+ mice resemble 
those found in mouse models of human mutations in patients with autosomal recessive 
familial Parkinson’s disease. Mice lacking either PTEN-induced kinase 1 (Pink1, also known 
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as Park6; ref. (Kitada et al., 2007)) or the novel glyoxylase DJ-1 (Park7; refs. (Goldberg et 
al., 2005; Lee et al., 2012)) exhibit decreased electrically evoked striatal dopamine release in 
the absence of changes in dopaminergic cell number or dopamine synthesis and metabolism. 
Decreased spontaneous locomotion is observed with both mutations but is not evident in 
PINK1-deficient mice until late adulthood (Gispert et al., 2009). Conversely, mice deficient 
in the E3 ubiquitin ligase parkin (Park2) exhibit increased striatal dopamine release while 
also showing decreases in both spontaneous and drug-stimulated locomotion without changes 
in dopaminergic cell number, striatal TH, or striatal dopamine content (Goldberg et al., 2003; 
Itier et al., 2003). In contrast to loss of UBE3A, in which dopamine reuptake appears to be 
functionally normal, loss of either PINK1 or parkin is associated with decreased striatal DAT 
levels and function, while mice deficient in DJ-1 have normal DAT levels but increased 
dopamine reuptake and decreased behavioral and physiological sensitivity to D2 receptor 
agonists (Goldberg et al., 2005). Of note, while radionuclide imaging has confirmed loss of 
presynaptic dopamine in the striatum of patients with PINK1- (Khan et al., 2002), DJ-1– 
(Dekker et al., 2003), and parkin-associated early-onset Parkinson’s disease (Scherfler et al., 
2004), no similar imaging findings or clinical measures of monoamines and their metabolites 
in cerebrospinal fluid have been published in studies of patients with AS.  
Converging lines of evidence suggest that defects of the ubiquitin-proteasome 
pathway may underlie some forms of human movement disorders, particularly those 
involving neurodegenerative processes (Ross and Pickart, 2004). For example, some early-
onset forms of Parkinson’s disease are caused by loss-of-function mutations in genes 
encoding parkin, PINK1, and DJ-1, while mutations in the gene encoding α-synuclein 
(SNCA) have been found in both autosomal dominant and sporadic forms of the disease. As 
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mentioned, parkin itself is an E3 ubiquitin ligase, which together with PINK1 and DJ-1 forms 
a complex to promote ubiquitination and degradation of parkin substrates (Xiong et al., 
2009). Parkin has been shown to specifically ubiquitinate and increase proteasomal turnover 
of a number of proteins, including O-glycosylated α-synuclein (αSp22; ref. (Shimura et al., 
2001)), which when overexpressed are toxic to monoaminergic neurons (Zhang et al., 2000; 
Imai et al., 2001; Choi et al., 2003; Ko et al., 2005; Wang et al., 2008). Misfolded α-
synuclein or excessive levels of α-synuclein are associated with dopaminergic cell death in 
Parkinson’s disease and can inhibit ubiquitin-proteasomal activity (Tanaka et al., 2001; 
Snyder et al., 2003). Data from cell culture suggest that α-synuclein may be a substrate for 
UBE3A, but there is no evidence for elevated α-synuclein levels in the absence of UBE3A in 
vivo (Mulherkar et al., 2009), consistent with normal numbers of midbrain dopaminergic 
neurons in Ube3am–/p+ mice. Increasing α-synuclein expression reduces dopamine release by 
interfering with vesicle recycling before neurodegeneration occurs, consistent with the 
reduced dorsal striatal dopamine release we observed in Ube3am–/p+ mice (Nemani et al., 
2010). It has been shown that dopaminergic VTA neurons are resistant to the toxic effects of 
α-synuclein overexpression (Maingay et al., 2006), but it is unknown whether or how α-
synuclein affects dopamine release in the NAc. In light of these observations, our data further 
support the possibility that disorders of ubiquitination can lead to functional changes in 
neural circuits in the absence of neurodegeneration (Shenoy and Lefkowitz, 2003; Hislop and 
von Zastrow, 2011).  
L-DOPA is a mainstay of therapy for Parkinson’s disease but can be accompanied by 
significant adverse effects. For example, patients with early-onset Parkinson’s disease with 
parkin mutations are exquisitely sensitive to L-DOPA but are also significantly more likely to 
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develop limiting dyskinesias and psychiatric complications while on L-DOPA therapy (Khan 
et al., 2003). In patients with Parkinsonism, replacement therapy with L-DOPA or directly 
acting dopaminergic agonists is aimed at ameliorating motor symptoms mediated by the 
dorsal striatum. However, such therapy consistently leads to adverse effects on reward-
mediated behaviors involving the NAc (Macdonald and Monchi, 2011). These observations, 
together with our findings that dopaminergic dysfunction in AS may be pathway specific, 
raise a cautionary note for ongoing clinical trials of L-DOPA in individuals with AS. Such 
studies may benefit from additional outcome measures, particularly neuropsychiatric indices, 
to ensure that L-DOPA treatment does not lead to unanticipated outcomes in patients with 
AS.  
4.5. Methods 
Animals. Male C57BL6/J WT and maternally deficient Ube3am–/p+ mice were used in 
all instances. These mice were generated from pairings of paternally deficient females with 
WT males. Age of mice ranged from P90 to P120. Mice used for ICSS were implanted at 
P65.7 ± 7.8 days and fully trained for the start of behavioral assessment with cocaine at 
P105.5 ± 18.1 days; raclopride at P131.3 ± 17.9 days; L741,626 at P155.3 ± 16.7 days; SCH 
23390 at P164.5 ± 16.2 days; or GBR 12909 at P197.3 ± 12.7 days. Animals were kept on a 
12-hour-dark/light cycle and given ad libitum access to food and water. All experiments 
(with the exception of Western blots) were performed blinded to genotype.  
ICSS. ICSS was performed as detailed previously (Fish et al., 2010). Briefly, mice (26 WT 
and 27 Ube3am–/p+ mice) were anesthetized (120 mg/kg ketamine, 9 mg/kg xylazine; 
Hospira), and 0.25% bupivacaine (Hospira) was applied to the scalp incision site. A stainless 
steel monopolar stimulating electrode (0.28-mm diameter; Plastics One) was stereotaxically 
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implanted into the MFB at the following coordinates relative to bregma: anterior/posterior 
(A/P) –1.3 mm; medial/lateral (M/L) +1.1 mm; dorsal/ventral (D/V) from skull surface –5.0 
mm (Paxinos G, 2001). Stimulating electrodes were insulated with polyamide, leaving 
approximately 0.25 mm of the tip exposed. The electrical ground was an uninsulated 
stainless steel wire (0.125-mm diameter) wrapped around a stainless steel screw threaded 
into the skull. Electrode assemblies were secured to the skull with dental cement.  
Following 1 week of recovery, mice were trained on a continuous (FR-1) schedule of 
reinforcement by the delivery of rewarding electrical stimulation (BSR) in a sound-
attenuated operant chamber (Med Associates) equipped with a wheel manipulandum. Each 
quarter turn of the wheel was reinforced by 500 ms of unipolar cathodal square-wave current 
paired with illumination of the house light as a secondary reinforcer. Mice were presented 15 
descending stimulation frequencies in discrete 0.05 inverse log steps, ranging from 126 to 25 
Hz (100-μs pulse width). Each frequency trial lasted 1 minute and consisted of a 5-second 
priming phase of noncontingent stimulation; 50-second active phase, during which BSR was 
available; and ended with a 5-second time out, during which further responses received no 
additional stimulation. The minimum current intensity required to maintain responding 
(minimum of 40 responses per minute) for the highest 3 to 5 frequencies was determined for 
each individual mouse and kept constant for the duration of the experiment. For SCH 23390, 
raclopride, and L741,626 experiments, the current was adjusted to maintain responding for 
the top 8–12 frequencies. Each test session consisted of 45 minutes (15 frequencies for 3 
repetitions) before injection and 60 minutes after injection. For GBR 12909 and L741,626, 
mice were placed into their home cage for 30 minutes following injection, followed by either 
90 minutes (6 series repetitions for GBR 12909) or 75 minutes (5 series repetitions for 
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L741,626) of access to BSR. BSR thresholds before injection (50% of maximum asymptotic 
response rate [EF50]) were calculated from the average of the second and third series (the 
first series was considered a “warm-up” and was discarded) and used as daily baselines for 
comparison to BSR thresholds after injection. 
Changes in BSR threshold were evaluated following i.p. injection of cocaine (1.0, 3.0, 
5.6, 10.0, 17.0 mg/kg, calculated as the free base; 26 WT and 27 Ube3am–/p+ mice; Sigma-
Aldrich), raclopride (0.03, 0.1, 0.178, 0.3 mg/kg; 9 WT and 12 Ube3am–/p+ mice; Sigma-
Aldrich), L741,626 (1.0, 1.78, 3.0, 5.6 mg/kg; 6 WT and 9 Ube3am–/p+ mice; Sigma-Aldrich); 
SCH 23390 (0.003, 0.01, 0.03, 0.1 mg/kg; 8 WT and 12 Ube3am–/p+ mice; Sigma-Aldrich); 
GBR 12909 (1.0, 3.0, 10.0, 17.0 mg/kg; 7 WT and 9 Ube3am–/p+ mice; Sigma-Aldrich); and 
normal saline or distilled water (vehicle for 741,626). All mice were assessed with cocaine 
and then divided into 2 groups, with one group of mice being tested with raclopride and 
L741,626 and the other group being tested with SCH 23390 and GBR 12900. Each dose was 
replicated 1–2 times and averaged for each mouse’s behavioral response.  
Locomotor behavior. Locomotion was measured in unlit sound-attenuated chambers 
(27.3 cm × 27.3 cm; Med Associates) and quantified by beam breaks of a 16 × 16 photobeam 
infrared array. Mice were placed in the chamber for 15 minutes of habituation, injected i.p. 
with normal saline or cocaine, and locomotion after injection was monitored for 45 minutes. 
Animals were habituated to the chamber and injection stress (saline) for 4 days, and the 
fourth day was used as baseline locomotor activity. Following baseline determination, mice 
were injected with cocaine daily, and cocaine-stimulated locomotor activity was assessed for 
6 consecutive days. Following 6 days of cocaine abstinence, during which animals remained 
in their home cages, locomotion after cocaine challenge was evaluated on day 7. 36 WT and 
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36 Ube3am–/p+ mice were divided into 3 separate groups of 12, receiving either sensitizing 
doses of 5.6, 10.0, or 17.0 mg/kg cocaine for the entirety of the experiment.  
TH immunohistochemistry. Mice (6 WT and 5 Ube3am–/p+ mice) were deeply 
anesthetized (120 mg/kg pentobarbital, i.p.) and perfused transcardially with 0.1 M PBS (pH 
7.4), followed by 4% paraformaldehyde in 0.1 M PBS. All brains were post-fixed by 
submersion in the same fixative for 24 hours and then cryoprotected in 10% sucrose for 24 
hours followed by 30% sucrose for 24 hours. Brains were sectioned (40 μm, coronal) on a 
sliding microtome and stored in cryoprotectant (1.0% polyvinylpyrrolidone [w/v], 30% 
sucrose [w/v], and 30% ethylene glycol [v/v] in 0.1 M PBS). Endogenous peroxidase activity 
was quenched with 1% hydrogen peroxide in 0.1 M PBS for 30 minutes at room temperature. 
Sections were blocked in 5% normal goat serum (NGS) and 2% Triton X-100 in 0.1 M PBS 
for 24 hours at room temperature and then incubated in rabbit α-rat TH primary antibody 
(1:2,000; AB152, Millipore) in 2% NGS and 2% Triton for 4 days at 4°C. Sections were 
washed (3 times) in 0.1 M PBS and incubated with HRP-conjugated goat α-rabbit secondary 
antibody (1:250; 31460, Thermo Scientific) in 2% NGS and 2% Triton at room temperature 
for 3 hours. Reaction product was visualized with a DAB Peroxidase Substrate Kit (SK-
4100; Vector Laboratories). Sections were mounted on potassium dichromate/gelatin-subbed 
slides and counterstained with cresyl violet for Nissl.  
Stereological quantification of cell numbers. The total number of TH-positive cells 
in the SNc and VTA was estimated with design-based stereology using StereoInvestigator 
v9.14 (MBF Bioscience) on a Microphot FXA microscope (Nikon). Every other section 
(section interval = 2) was immunostained and counted, yielding on average 12 midbrain 
sections per animal. The borders of the SNc and the VTA at all rostrocaudal levels in the 
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midbrain were delineated at low (×4) magnification based on the standard mouse atlas 
(Paxinos G, 2001). For purposes of this study, the VTA and SNc were divided by a line 
connecting the medial border of the medial lemniscus, dorsally, to the medial edge of the 
corticospinal tract, ventrally, in all sections. Counting frames (50 μm × 50 μm) were 
randomly placed and systematically moved through a sampling grid (120 μm × 120 μm) by 
the software via a motorized stage (Ludl Electronic Products). An optical disector height of 
12.0 μm, flanked by 2.0-μm guard zones on top and bottom, was applied to all counting 
frames based on average section shrinkage estimates. Bright-field counting under direct 
visualization was performed at ×100 oil magnification (NA = 1.4). Estimates of the total 
numbers of TH-immunostained neurons were calculated using the optical fractionator 
method (West, 1999). For all estimates, coefficients of error ≤ 0.10 were accepted 
(Gundersen and Jensen, 1987). Using this protocol, results were obtained that are in 
agreement with estimates of numbers of dopaminergic SNc neurons in C57BL6/J mice using 
other methods (Baquet et al., 2009).  
TH and Ube3a immunofluorescence colocalization. 2 WT and 2 Ube3am–/p+ mice 
were transcardially perfused with 4% paraformaldehyde, and their brains were post-fixed, 
cryoprotected, and sectioned on a sliding microtome as described above. Tissue sections 
were rinsed thoroughly in Tris-buffered saline plus 0.3% Triton X-100 (TBST, pH 7.5) prior 
to being incubated at 80°C for 20 minutes in 10 mM sodium citrate buffer (pH 6.0) for 
antigen retrieval. Subsequently, sections were rinsed in TBST and blocked for 25 minutes in 
TBST containing 4% nonfat dry milk. Blocked sections were then incubated for 2 days at 
4°C in the same blocking solution containing sheep anti-TH (1:1,000; Pel-Freez) and mouse 
anti-Ube3a (1:200; clone 330, Sigma-Aldrich) primary antibodies. Sections were then rinsed 
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with fresh blocking solution prior to incubation for 1 hour at room temperature in 
biotinylated donkey anti-mouse IgG (1:250; Jackson ImmunoResearch Laboratories Inc.) and 
Alexa Fluor 488 donkey anti-sheep secondary antibodies (Invitrogen). Following several 
rinses in TBST, sections were incubated for 1 hour at room temperature in Alexa Fluor 568–
streptavidin (2 μg/ml in TBST). Tissue was mounted on subbed slides and coverslipped with 
DPX. Images were taken using confocal microscopy (LSM710, Zeiss).  
Tissue punches. Mice were deeply anesthetized with sodium pentobarbital, and 
brains were snap frozen in methylbutane on dry ice. Brains were serially sectioned on a 
cryostat, until reaching the rostral pole of the NAc. Tissue punches (pooled from both 
hemispheres) were taken from the NAc and dorsolateral striatum (17 and 15 gauge, 
respectively). Punches were stored at –80°C until use. 
Western blotting. Tissue punches from the NAc and striatum (8 WT and 8 Ube3am–/p+ 
mice) were treated with 100 μl lysis buffer (50 mM Tris-HCl, 8.0 pH, 150 mM NaCl, 1% 
Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate). To assess TH protein levels, 20 μg of 
total protein lysates from WT and Ube3am–/p+ tissue homogenate were separated by 4%–12% 
SDS-polyacrylamide gel electrophoresis. Proteins were then transferred to nitrocellulose 
membranes, and immunoblotting was performed using a sheep anti-TH antibody (1:1,000; 
Pel-Freez), followed by IRDye800CW-conjugated donkey anti-sheep IgG (1:1,000; 
Rockland) and mouse anti–β-actin antibody (1:1,000; Sigma-Aldrich), followed by Alexa 
Fluor 680–conjugated goat anti-mouse IgG (1:5,000; Invitrogen). Protein bands were 
visualized by an Odyssey system (LI-COR Biosciences). To control for protein loading, TH 
protein levels were normalized to β-actin levels detected in each sample.  
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HPLC. Tissue punches from the NAc and dorsal striatum (5 WT and 6 Ube3am–/p+ 
mice) were weighed and mixed with 200 μl 0.1 N HClO4 containing 1 μM hydroquinone, the 
internal standard. Tissue was homogenized using a sonic dismembrator (model 60; Fisher 
Scientific). The homogenate was then centrifuged at 10,000 g for 10 minutes, and the 
supernatant was removed and filtered using a 0.2-μm syringe filter (Millex-LG; Millipore). 
HPLC was employed, using a modified method of Mefford (Mefford, 1981). Briefly, 20 μl 
injections were made onto a revered-phase column (5 μm, 4.6 mm × 5 mm; Waters Atlantis). 
The mobile phase contained 0.1 M citric acid, 1 mM sodium hexylsulfate, 0.1 mM EDTA 
(pH = 3), and 10% methanol as the organic modifier at a flow rate of 1.0 ml/min. 
Neurotransmitters were detected with a thin-layer radial electrochemical cell (BASi) at a 
potential of +800 mV vs. the Ag/AgCl reference electrode. Data were collected at 60 Hz 
using a LabVIEW strip chart recorder program (Jorgenson Lab; University of North Carolina 
at Chapel Hill) and homebuilt electronics. The peak area of the analyte was ratioed to the 
peak area of the internal standard, and the analyte concentration in the tissue was calculated. 
Stock solutions were made to be 10 mM in 0.1 N HClO4, and response ratios were 
determined daily using 2 μM solution mixtures.  
FSCV. Mice (NAc, 11 WT and 8 Ube3am–/p+ mice; dorsal striatum, 7 WT and 9 
Ube3am–/p+ mice) were anesthetized with urethane (1.5 g/kg body) and affixed in a 
stereotaxic frame (David Kopf Instruments). Stereotaxic craniotomies were performed, and a 
carbon-fiber microelectrode was implanted in either the NAc (from bregma, A/P +1.1, M/L 
+1.2, D/V from skull surface –3.5 to –4.0) or dorsal striatum (from bregma, A/P +0.5, M/L 
+2.5, D/V from skull surface –2.5 to –3.0) (Paxinos G, 2001). A bipolar stainless steel 
stimulating electrode, insulated to the tip (0.2-mm diameter; Plastics One), was implanted 
92 
 
into the MFB (bregma, A/P –1.2, M/L +1.0, D/V from skull surface –5.0), and an Ag/AgCl 
reference electrode was implanted into the contralateral hemisphere. Computer-generated 
biphasic pulse trains, 2 ms in width and 325 μA each phase, were applied through constant 
current stimulators (NL 800A; Neurolog, Medical Systems Corp.), for 24 pulses at 20, 30, 
40, 50, and 60 Hz to evoke dopamine release. Stimulation-evoked release was recorded 
during and after the stimulation. GBR 12909 (20 mg/mg, Sigma-Aldrich) was dissolved in 
saline and injected i.p. at a volume of 1 ml/kg.  
Glass-encased, cylindrical carbon-fiber microelectrodes and Ag/AgCl reference 
electrodes were prepared as described previously (Cahill et al., 1996). Briefly, carbon-fiber 
microelectrodes were constructed by vacuum aspiration of a single T-650 carbon fiber 
(Thornel, Amoco Co.) into a glass capillary of 0.6-mm external diameter and 0.4-mm 
internal diameter (A-M Systems, Inc.). A micropipette puller (Narishige) was used to taper 
the glass and form a carbon-glass seal. The exposed carbon fiber was cut to approximately 
100 μm in length and was soaked for 30 minutes in isopropyl alcohol to clean the surface. 
Application of the voltage waveform and data collection for FSCV were computer controlled 
and have been described in detail previously (Heien et al., 2003). Briefly, a triangular scan (–
0.4 to +1.3 V, 400 V/s) was repeated every 100 ms. Data were digitized and stored on a 
computer using software written in LABVIEW (National Instruments). Background-
subtracted cyclic voltammograms were obtained by digitally subtracting voltammograms 
collected during baseline recording from those collected during stimulation. A custom-built 
UEI potentiostat (Department of Chemistry Electronics Facility, University of North 
Carolina at Chapel Hill) was used. All potentials are reported compared with the Ag/AgCl 
reference electrode. Signal processing (background subtraction, signal averaging, and digital 
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filtering) (4-pole Bessel Filter, 2 kHz) was also performed by the software. All signals were 
verified as dopaminergic by the shape of their cyclic voltammogram as well as by their 
response to GBR 12909, a selective inhibitor of the DAT. Data were analyzed and plotted 
using TH-1 software.  
ICSS and FSCV electrode placement verification. Mice used for ICSS were deeply 
anesthetized with sodium pentobarbital and intracardially perfused with 0.9% saline followed 
by 4% paraformaldehyde in 0.1 M PBS. Mice used for FSCV were anesthetized with sodium 
pentobarbital, and brains were removed and drop fixed in 4% paraformaldehyde in 0.1 M 
PBS. The brains were sectioned (50 μm) on a sliding microtome, stained with cresyl violet 
for Nissl, and viewed under low-powered (×4) light microscopy to determine the location of 
the most ventral electrode tip placements (Supplemental Figures 5 and 6). 
Statistics. SigmaPlot (Systat Software) was used for statistical analysis. Mann-
Whitney tests were run to compare baseline reward thresholds (EF50), baseline maximum 
response rates, or basal locomotor activity between genotypes. All other comparisons were 
based on a repeated-measures model that included a genotype-by-dose (ICSS), genotype-by-
day (locomotor activity), genotype-by-second (FSCV), or genotype-by-stimulation frequency 
(FSCV) interaction. All genotype contrasts (Holm-Sidak) were performed based on these 
models and reported when significant. An additional comparison between day 1 and 
challenge was performed for locomotor activity experiments to determine whether 
sensitization occurred. Corrections for multiple comparisons were made for FSCV 
experiments based on the genotype-by-second model. Level of significance for all reported 
effects was placed at P < 0.05.  
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Study approval. All experimental animal procedures were carried out according to the 
NIH Guide for the Care and Use of Laboratory Animals and the Society for Neuroscience 
Policy on the Use of Animals in Neuroscience Research and were approved by the 
Institutional Animal Care and Use Committee at the University of North Carolina at Chapel 
Hill.  
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Figure 4-1: Ube3am–/p+ mice are more sensitive to BSR but less sensitive to dopaminergic 
potentiation of BSR. (A) Representative ICSS rate-frequency curves in a WT mouse. 
Injection (i.p.) of the DAT antagonist GBR 12909 dose-dependently increases responding for 
rewarding electrical current at lower stimulus frequencies. (B) Rate-frequency curves 
expressed as charge (Q) delivery at each frequency (Hz) from Ube3am–/p+ mice are shifted to 
the left compared with those of WT littermates. (C) Ube3am–/p+ mice require significantly 
less (***P < 0.001) charge to evoke the same degree of responding as WT mice at reward 
threshold frequencies (EF50). (D) The maximum rate of operant responding for rewarding 
brain stimulation is comparable between genotypes (P > 0.05). (E) Ube3am–/p+ mice maintain 
a lower reward threshold over time (16–30 minutes, ***P < 0.001; 31–45 minutes, ***P < 
0.001; 46–60 minutes, *P = 0.026). (F) WT mice exhibit greater potentiation of rewarding 
brain stimulation expressed as lower reward thresholds than Ube3am–/p+ mice following 10.0 
mg/kg (**P = 0.002) and 17.0 mg/kg (***P < 0.001) GBR 12909 (i.p.). Error bars indicate ± 
SEM in B, E, and F and the median and interquartile ranges in C and D. 
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Figure 4-2: Ube3am–/p+ mice exhibit normal BSR threshold responses to cocaine and 
selective D1 and D2 dopamine receptor antagonists but decreased sensitivity to D2-
dependent motor impairment. BSR threshold was determined following i.p. administration 
of (A–C) cocaine, (D) the D1 receptor antagonist SCH 23390, or the D2-selective 
antagonists (E) raclopride or (F) L741,626. (A–C) Cocaine had similar potency on BSR 
threshold in both genotypes at its peak effect (0–15 minutes), but its rewarding effects 
decayed more slowly in Ube3am–/p+ mice (46–60 minutes, 10.0 mg/kg, *P = 0.025; 17.0 
mg/kg, #P < 0.001). (D) The D1 antagonist SCH 23390, (E) the D2-like antagonist 
raclopride, or (F) the highly D2-selective antagonist L741,626 equally elevated reward 
thresholds of WT and mutant mice. (G) However, while D1 receptor antagonism had similar 
depressant effects on maximum operant response rates of both genotypes, antagonism of D2 
receptors with either (H) raclopride (0.178 mg/kg, **P = 0.005; 0.3 mg/kg, #P < 0.001) or (I) 
L741,626 (5.6 mg/kg, #P < 0.001) had greater depressant effects on maximum response rates 
of WT mice. Error bars indicate ± SEM. 
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Figure 4-3: Cocaine-stimulated locomotion is lower in Ube3am–/p+ mice. Psychostimulant-
induced locomotion in 3 separate groups of mice (12 WT and 12 Ube3am–/p+ mice per group) 
injected with 5.6, 10.0 or 17.0 mg/kg i.p. cocaine for 6 consecutive days and a final challenge 
dose 1 week later. (A–C) Distance traveled is binned in 1-minute increments. (D–F) The sum 
of the first 15 minutes following injection is plotted below each of their respective treatment 
groups. (D) A deficit in the locomotive response of Ube3am–/p+ mice emerges after 3 days of 
5.6 mg/kg cocaine administration (P = 0.02; day 5, P = 0.031; challenge, P = 0.031) and (E) 
by the second day of 10.0 mg/kg cocaine (P = 0.009; day 3, P = 0.012; day 4–6, P < 0.001). 
(F) High-dose (17.0 mg/kg) cocaine elicits an attenuated response after the first 
administration in Ube3am–/p+ mice that is gone by the fourth day. (D–F) Cocaine-induced 
sensitization occurred at all 3 doses for both genotypes (day 1 vs. challenge, P < 0.001). 
Error bars indicate SEM. *P < 0.05; #P < 0.01; †P < 0.001. 
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Figure 4-4: Biochemical and anatomical markers of the mesolimbic and nigrostriatal 
dopaminergic pathways are normal in Ube3am–/p+ mice. (A) Immunohistochemistry 
showing imprinting of UBE3A in the mesencephalic VTA and SNc and colocalization with 
TH in WT mice (original magnification, ×4). Boxed regions are shown at higher 
magnification in the second, third, and fourth columns (original magnification, ×40). (B) 
Numbers of TH-positive cells in the VTA and SNc estimated with design-based stereology 
show no differences between WT and Ube3am–/p+ mice. Ventral midbrain image is magnified 
(original magnification, ×4) and the boxed region is shown at higher magnification to the 
right (original magnification, ×40). (C) Quantification of TH, the rate-limiting enzyme in 
dopamine biosynthesis, from NAc and striatal tissue punches by immunoblotting shows 
similar levels between the 2 genotypes. (D) HPLC analysis of concentrations of dopamine 
and (E) its primary acid metabolite DOPAC in NAc and striatal punches from WT and 
Ube3am–/p+ mice shows similar tissue content of dopamine and DOPAC. (F) 
Dopamine/DOPAC ratios are also equivalent between genotypes in NAc and striatum. Error 
bars indicate SEM. Numbers in bars represent numbers of mice. 
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Figure 4-5: Dopamine release is enhanced in NAc and reduced in dorsal striatum of 
Ube3am–/p+ mice. Comparison of dopamine (DA) release measured with in vivo FSCV in the 
(A) NAc (on left throughout) and (B) dorsal striatum (on right throughout) of Ube3am–/p+ 
mice and their WT littermates. (A and B) Traces represent changes in dopamine 
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concentration evoked by 60-Hz stimulation (stimulus duration shaded gray). Insets show 
peak concentration of evoked dopamine in individual animals. (C and D) Average of peak 
concentrations evoked by stimulation frequencies, ranging from 20 to 60 Hz (NAc, 30 Hz, P 
= 0.05; 40 Hz, P = 0.008; 50 Hz, P = 0.045; 60 Hz, P = 0.004; striatum, 30 Hz, P = 0.006; 40 
Hz, P = 0.002; 50 Hz, P = 0.015). (E–H) Extracellular dopamine concentrations following 5 
discrete frequency stimulation steps, ranging from 20 to 60 Hz in the (E and G) NAc or (F 
and H) dorsal striatum. (I and J) Response of electrically stimulated (60 Hz) dopamine 
release to GBR 12909 (20 mg/kg), 30 minutes after i.p. injection. Insets show the relative 
increase in dopamine release (area under the curve) following GBR 12909. Error bars 
indicate SEM. Numbers in bars represent numbers of mice. *P < 0.05; #P < 0.01; †P < 0.001. 
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Table 1: Anatomical markers of dopamine 
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Table 2: Biochemical markers of dopamine 
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Supplemental Figure 4-1:  Schematic of rate-dependent intracranial self-stimulation 
(ICSS).  (A) Mice implanted with monopolar stimulating electrodes to the medial forebrain 
bundle (MFB) at the level of the lateral hypothalamus receive rewarding brain stimulation 
(BSR) for every quarter wheel turn, accompanied by illumination of the house light (500 ms).  
(B) Mice are presented with 15 discrete descending frequency steps (0.05 inverse log units) 
over 15 minutes. Mice have ad libitum access to BSR for 50 seconds during each frequency 
presentation. The minimum stimulus amplitude (µA) needed to initiate wheel turning for the 
top 3-5 frequencies is determined for each mouse and kept constant for the rest of the 
experiment. Injection of drugs that increase forebrain dopamine release (e.g., 5.6 mg/kg 
cocaine) decrease reward threshold (EF50) such that lower frequency stimulation sustains 
responding.  (C) Schematic of the VTA-NAc reward circuit.  Stimulation of ascending axons  
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(MFB) from the VTA results in the release of dopamine from their terminal fields in the 
NAc.  Dopaminergic release in the NAc can be increased pharmacologically by blocking 
dopamine transporters with cocaine or GBR 12909, increasing extracellular dopamine 
availability. 
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Supplemental Figure 4-2:  Changes in BSR threshold following pharmacological 
treatment Reward threshold (EF50) was determined following i.p. administration of 
drugs that affect dopaminergic neurotransmission.  (A) Cocaine lowered BSR threshold 
to the same extent in both Ube3am-/p+ and WT mice (0-45 min), but its effect decayed more 
rapidly in WT mice by 45-60 min (10 mg/kg, *p = 0.025; 17 mg/kg, ***p < 0.001).  (B) The 
highly-selective (DAT) blocker GBR 12909 consistently lowered reward threshold more in 
WT mice than m-/p+ littermates for the first 105 minutes following injection (30-45 min, 
10.0 mg/kg, **p = 0.002, 17.0 mg/kg, *p < 0.036; 46-60 min, 10.0 mg/kg, **p = 0.003, 17.0 
mg/kg ***p < 0.001; 61-75 min, 10.0 mg/kg, **p = 0.002, 17.0 mg/kg, ***p < 0.001; 76-90 
min, 17.0 mg/kg, ***p < 0.001; 91-105 min, 10.0 mg/kg, *p = 0.014, 17.0 mg/kg, **p =  
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0.01).  (C) There were no significant genotype differences in the threshold-elevating effects 
of the dopamine D1-receptor antagonist SCH 23390  Neither administration of the D2/D3 
antagonist raclopride (D) nor the D2-selective antagonist L741,626 (E) elevated reward 
threshold to a greater extent in either genotype.  Error bars indicate ±SEM. 
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Supplemental Figure 4-3:  Maximum operant response rate following pharmacological 
treatment. (A) WT mice exhibited a significantly larger increase in their maximum response 
rate 31-45 min after i.p. cocaine injection (10 mg/kg, *p = 0.028; 17 mg/kg, **p = 0.001).  
(B) WT mice also exhibited a significantly larger increase in their maximum response rate 
76-105 min after i.p. GBR 12909 injection (76-90 min, 10 mg/kg, *p = 0.032, 17 mg/kg, *p 
= 0.015; 91-105 min, 10 mg/kg, *p = 0.018, 17 mg/kg, **p = 0.004).  (C) There was no 
significant difference in reduction of maximum operant response rate following SCH 23350 
injection between genotypes at any time point after i.p. administration.  (D) Ube3am-/p+ mice 
were significantly less sensitive than WT littermates to the depressant effects of the D2/D3 
antagonist raclopride on maximum operant response rate (16-30 min, 0.178 mg/kg, **p =  
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0.005, 0.3 mg/kg, ***p < 0.001).  (E) Ube3am-/p+ mice were also less sensitive to the effects 
of the selective D2 antagonist L741,626 on maximum response rate (30-45 min, 5.6 kg/mg, 
***p < 0.001; 46-60 min, 5.6 kg/mg, ***p < 0.001; 61-75 min, 5.6 kg/mg, ***p < 0.001; 76-
90 min, 5.6 kg/mg, ***p < 0.001).  Error bars indicate ±SEM. 
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Supplemental Figure 4-4:  Enhanced extracellular dopamine in the NAc and reduced 
extracellular dopamine in the dorsal striatum of Ube3am-/p+ mice. Change in extracellular 
dopamine concentration measured by voltammetry following electrical stimulation of the 
ascending dopaminergic fibers to either the NAc (A) or dorsal striatum (B).  Insets show the 
peak dopamine concentration recorded from each mouse. The stimulus duration is shown in 
gray shading.  (A) Ube3am-/p+ mice consistently exhibited greater accumbal NAc dopamine 
concentrations across all stimulation frequencies (20-50 Hz, above, and 60 Hz in Figure 5A).  
(B) Conversely, in the dorsal striatum extracellular dopamine was reduced in Ube3am-/p+ 
mice (20-50 Hz, above, and 60 Hz in Figure 5B).  *p < 0.05, **p < 0.01, ***p < 0.001.  Error 
bars indicate ±SEM. 
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Supplemental Figure 4-5:  ICSS electrode placement. Mice used for ICSS experiments 
were perfused and their brains sectioned and stained for Nissl to determine electrode tip 
placements.  (A) Representative coronal section (4x magnification) with a stimulating 
electrode tract directly above the MFB.  (B) All electrodes were implanted on the right.  The 
most ventral point of each electrode tract was determined and plotted on the left for WT mice 
(gray circles) and on the right for Ube3am-/p+ mice (red circles) for clarity. 
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Supplemental Figure 4-6:  FSCV electrode placement.  Mice used for FSCV experiments 
were perfused and their brains sectioned and Nissl stained to determine electrode tip 
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placements.  (A) Representative placements for carbon-fiber microelectrodes in the NAc.  
(B) Representative placements for carbon-fiber microelectrodes in the dorsal striatum.  (C) 
Representative placements for bipolar stimulating electrodes in the MFB.  The two tips of 
each bipolar electrode are connected with horizontal lines.  The most ventral point of each 
electrode tract was determined and plotted on the left for WT mice (gray circles) and on the 
right for Ube3am-/p+ mice (red circles). 
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CHAPTER 5 
 
5. Concluding Remarks and Future Directions 
5.1. Experience-dependent plasticity in Angelman syndrome  
We discovered a reduction in neocortical plasticity in Angelman syndrome (AS) 
model mice.  Both long-term potentiation and depression (LTP and LTD respectively) of 
layer IV to II/III field excitatory postsynaptic potentials (fEPSC) were severely impaired in 
visual cortical brain slices.  The in vitro LTD deficit was associated with impaired critical 
period ocular dominance plasticity, an LTD-contingent form of experience-dependent 
plasticity.  However, while AS mice also exhibited impaired LTP of layer IV to II/III fEPSCs 
during the critical period (~P25), there were no deficits in stimulus-specific response 
potentiation (SRP), an LTP-contingent form of experience-dependent plasticity.  
Furthermore, while the deficit in LTP of layer IV to II/III synapses was even more profound 
in adult mice (~P100), experience-dependent potentiation was surprisingly enhanced, relative 
to wild-type (WT) mice.     
5.1.1. In vitro LTP versus In vivo experience-dependent potentiation 
There are several possible reasons for the apparent inconsistency between in vitro 
electrically-induced potentiation and in vivo visual experience-induced potentiation in AS 
mice.  Field recordings conducted in brain slices measured LTP of layer IV to II/III synapses, 
but visual evoked potentials (VEP) were recorded from electrodes implanted in layer IV and 
consist primarily of thalamocortical responses (Muhammad et al., 2009).  It is conceivable 
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that there are layer specific deficits in LTP induction in AS, and that thalamocortical LTP 
induction is spared.  This seems unlikely to account for the discrepancy.  Although the 
negative component of the VEP response is attributed mostly to layer IV pyramidal cells, the 
positive component is believed to represent intracortical activity driven in part by layer II/III 
activity (Khibnik et al., 2010).  One might therefore expect that a deficit in layer II/III LTP 
induction would manifest in a smaller VEP amplitude (trough to peak), specifically in the 
peak amplitude, following SRP.  Both the increase in peak and trough components of the 
VEP were greater in AS mice.  However, because layer IV afferents directly activate layer 
II/III, it is difficult to rule out the possibility of layer IV compensation.   
A second factor that has to be considered is tetanic electrical stimulation versus 
sensory stimulation.  The method of stimulation can have a large impact on the magnitude of 
inhibition.  When stimulation consists of patterned sensory input, cortical inhibitory 
postsynaptic potentials lag behind excitatory postsynaptic potentials, whereas with electrical 
stimulation, inhibition and excitation are activated concurrently (Okun and Lampl, 2008; 
Logothetis et al., 2010).  Visual stimulation with spatio-temporally structured input patterns 
more naturally engages the visual circuit, than electrical stimulation, and may have had a 
profound influence on LTP induction in AS mice. This gets at the greater point that while 
there may be advantages of in vitro slice preparations, such as a relative ease of obtaining 
stable recordings from an isolated circuit, there are also disadvantages.  Neurons in a slice 
preparation lack many of the normal afferent input and efferent targets present in vivo, and so 
observations made in slice experiments have to be considered in light of their artificial 
setting, as opposed to the more complex environment of the intact brain. 
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Another striking difference between the electrical tetanus and sensory LTP induction 
is timing.  Two to three seconds of tetanic electrical stimulation is sufficient to immediately 
induce LTP.  On the other hand, potentiation of the VEP response, following presentation of 
patterned visual stimuli, takes at least 24 hours, and does not plateau until after 7-11 days of 
visual stimulation.  This leads to the question of whether SRP is an endogenous form of LTP 
analogous to that induced by tetanic electrical stimulation.  There are in fact several lines of 
evidence to suggest that SRP and electrical induced LTP share common molecular 
mechanisms.  Electrical stimulation of the dorsal lateral geniculate nucleus (dLGN) in vivo 
has been shown to significantly increase the amplitude of VEP responses (Heynen and Bear, 
2001), and remained stable for least 5 days (Cooke and Bear, 2010).  The augmented VEP 
response also occluded SRP.  Mice that received unilateral electrical stimulation of the 
dLGN, initially exhibited larger VEP responses in the stimulated hemisphere.  However after 
five days of subsequent visual stimulation, VEP amplitudes were no longer significantly 
different between the two hemispheres, indicating that the ceiling level for potentiation 
following electrically inducted LTP and SRP combined was equal to that of SRP alone 
(Cooke and Bear, 2010).  The reverse was also demonstrated following SRP, with electrical 
stimulation of the dLGN failing to further increase the VEP amplitude (Cooke and Bear, 
2010). 
In addition to SRP’s functional mimicry and occlusion of electrical LTP induction, 
SRP shares a number of molecular mechanisms with canonical LTP.  SRP is blocked by 
preinjection of the competitive NMDA receptor antagonist 3-(2-Carboxypiperazin-4-
yl)propyl-1-phosphonic acid (CPP), which also blocks LTP in visual cortical slices 
(Kirkwood et al., 1993; Frenkel et al., 2006).  Additionally, SRP is blocked by preventing 
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AMPA receptor insertion into the postsynaptic membrane, by transfection of the GluR1 C-
terminal domain, shown to exert a dominant negative effect on AMPA receptor insertion, and 
block LTP induction in hippocampal slices (Shi et al., 2001; Frenkel et al., 2006).  Lastly, 
maintenance of NMDA-dependent LTP is reliant of the persistently active protein kinase, 
protein kinase Mζ (PKMζ; (Pastalkova et al., 2006).  Local infusion of the ζ-inhibitory 
peptide (ZIP), which inhibits PKMζ, abolished the enhanced VEP response following SRP 
(Cooke and Bear, 2010).  These studies suggest that SRP likely represents an endogenous 
form thalamocortical LTP. 
5.1.2. Visual cortical inhibition 
Several recent studies have revealed a developmental decline in inhibition within the 
cerebellum and visual cortex of AS model mice (Egawa et al., 2012; Wallace et al., 2012).  
Adult (~P80) AS mice exhibited a deficit in inhibitory drive onto pyramidal neurons in layer 
II/III of the visual cortex, which was not present during the critical period (~P25).  The 
decline in visual cortical inhibition observed by Wallace et al. (2012) corresponded with the 
developmental augmentation of SRP that I had witnessed in AS mice.  To determine how 
loss of Ube3a expression in inhibitory neurons contributed to experience-dependent 
potentiation, I utilized CRE-LOX technology to limit maternal Ube3a expression to 
inhibitory neurons, using the GAD2 promoter (GAD2-CRE:Ube3astop/+).  Interestingly, when 
SRP was assessed in adult GAD2-CRE:Ube3astop/+ mice, the rate and degree of VEP 
potentiation was comparable to WT mice.  This further suggests that the enhanced adult SRP 
in AS mice may be due to the loss of Ube3a function in inhibitory neurons specifically.  
Electrophysiological recordings still need to be carried out to confirm that normal inhibitory 
drive onto excitatory neurons is present in the GAD2-CRE:Ube3astop/+ mice. 
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The documented deficits in both visual cortical inhibition and excitation in AS, led us 
to hypothesize that solely restoring inhibition would tip the balance of cortical activity in the 
direction of reduced excitatory drive.  It was therefore somewhat surprising that the 
magnitude of experience-dependent potentiation in GAD2-CRE:Ube3astop/+ mice was 
comparable to WT mice, and not attenuated.  However, the magnitude of potentiation to the 
orthogonal visual stimulus was diminished in the GAD2-CRE:Ube3astop/+ mice relative to 
WT mice.  It is difficult to decipher the meaning of this finding since very little of the SRP 
literature focuses on adult mice, when there is both stimulus-specific and nonspecific 
components to experience-dependent potentiation.  Determining the role of Ube3a in 
excitatory neurons and sensory experience will benefit from future studies that utilize CRE-
LOX system.  Using the same approach as the GAD2-CRE:Ube3astop/+ mice, Ube3a 
expression can be limited to excitatory neurons by having CRE recombinase under control of 
the CaMKII promoter.   
5.1.3. Orientation Selectivity 
Cortical inhibition plays an important role in turning orientation selectivity (Borg-
Graham et al., 1998; Shapley et al., 2003).  Elegant experiments that pharmacologically 
block cortical inhibition have been shown to reduce orientation selectivity (Sato et al., 1996).  
The reduction in cortical inhibition observed in AS may similarly result in broader tuning of 
orientation selectivity, but future single-unit recordings will have to be carried out to test this 
hypothesis.  A reduction in orientation selectivity of AS mice could result in a greater 
number of active neurons at any given stimulus orientation.  A greater number of active cells 
during SRP might further enhance the VEP response.  But a greater number of active cells 
would also presumably contribute to a larger baseline VEP response, which was not 
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observed.  The other factor that has to be kept in mind is the reduction in excitation.  While 
the reduction in inhibition might contribute to a greater number of responsive cells, the 
reduction in excitation could mean that each of those responsive cells is less active, and 
together generate a local field potential of comparable amplitude to WT mice at baseline.          
5.2. Inversely affected mesolimbic/nigrostriatal dopamine release 
Angelman syndrome has numerous characteristics that are potentially germane to 
dopaminergic function.  AS phenotypes like ataxia, tremor, and stereotypies, including hand-
flapping, tongue-thrusting, excessive chewing and mouthing behaviors, can be caused by an 
imbalance of dopamine in the nigrotriatal pathway.  On the other hand, AS phenotypes such 
as hyperactivity, excitable personality, reduced need for sleep, and happy demeanor can be 
related to dopaminergic transmission in the mesolimbic system.  Despite the potential 
relevance of dopamine function in AS, exploration of the basal ganglia has not been 
thoroughly pursued. 
I used fast-scan cyclic voltammetry (FSCV) to investigate the possibility that 
dopamine is dysregulated in AS model mice.  Voltammetric analysis revealed that stimulated 
release of dopamine was attenuated in the nigrostriatal system, and augmented in the 
mesolimbic system.  The enhanced stimulated dopamine release within the nucleus 
accumbens (NAc) corresponded behaviorally with an increased sensitivity to rewarding 
electrical stimulation.  It is tempting to speculate that the enhanced sensitivity to mesolimbic 
reward/pleasure may be related to the characteristic happy demeanor of AS.  Additionally, 
drugs that increase dopaminergic tone in the mesolimbic pathway are known to promote 
hyperactivity and wakefulness, observed in AS (Costall et al., 1984; Wisor et al., 2001).  The 
reduction in dopaminergic tone within the striatum can lead to tremor, and motor 
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impairments including cogwheel rigidity and bradykinesia, also reported in AS (Harbord, 
2001).  These reports of Parkinson-like motor impairments in AS have led to a clinical trial 
using dopamine replacement therapy (Harbord, 2001; Tan, 2012).  However, boosting 
dopamine synthesis with pharmaceuticals such as levodopa, not only increases dopaminergic 
tone in the nigrostriatal system to ameliorate motor function, it also increases dopamine 
synthesis in the ventral tegmental area (VTA) which could further exacerbate behaviors 
linked to mesolimbic function in AS (Macdonald and Monchi, 2011).  Therefore it is 
important to understand why stimulated dopamine release is inversely impacted in the 
mesolimbic/nigrostriatal pathways of AS. 
The differential release of dopamine in the mesolimbic/nigrostriatal pathways of AS 
mice could not be attributed to changes in dopamine cell number or dopamine availability.  
The number of tyrosine hydroxylase (TH) positive cells, the precursor and marker for 
dopamine, was unaltered in the VTA and substantia nigra pars compacta (SNc).  
Furthermore, the concentrations of TH, dopamine, and DOPAC, the metabolite of dopamine, 
in the terminal fields of the NAc and striatum were also unchanged in AS mice.  
Extracellular dopamine availability is also determined by the rate of neurotransmitter uptake 
through dopamine transporters (DAT), but this aspect of neurotransmission was also 
unaltered.  Neither the rate of dopamine clearance following stimulation, nor the increased 
concentration of extracellular dopamine following administration of the DAT blocker GBR 
12909, were different in AS mice using voltammetric analysis. 
5.2.1. D2 receptor function 
With differences in dopamine uptake, neuroanatomy and synthesis ruled out, another 
possibility is that the electrophysiological properties of the dopamine cells are altered in AS. 
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Because the VTA and SNc are highly modulated by inputs from several dozen brain 
structures, a reductionistic approach is required to evaluate the cell-autonomous properties of 
dopamine neurons (Zahm et al., 2011).  This can be achieved by recording from brain slices 
containing the VTA/SNc, in which the majority of inputs have been severed.  Dopamine 
neurons in this region can be identified based upon anatomical landmarks, and with the aid of 
transgenic mice that express EGFP under the TH promoter (Sawamoto et al., 2001; 
Matsushita et al., 2002).  Dopamine neurons also exhibit a characteristic large inward current 
(Ih) upon hyperpolarization of the membrane potential, detectable in whole-cell recordings 
(Johnson and North, 1992).  Once patched onto a dopamine neuron, its intrinsic excitability 
can be evaluated by measuring the input/output and frequency/current relationships.   
Dopaminergic excitability is regulated in part by D2 autoreceptors, which appears to be 
affected in AS.  While assessing brain stimulation reward (BSR), I discovered that AS mice 
were less sensitive to the motor disruptive effects of D2 antagonists, but equally sensitive to 
the depotentiating effects on reward threshold compared to WT mice.  This suggests D2 
function might be specifically affected in the nigrostriatal pathway.  However, it is difficult 
to rule out the possibility that D2 receptor function is altered in the mesolimbic system as 
well, since the BSR paradigm is sensitive to changes in motor function.  In addition, the 
antagonists were administered systemically, so that the reduction in sensitivity could be due 
to changes in D2 receptor function/availability in other brain regions that innervate the motor 
pathway.   
Questions of how and where D2 receptor function might be modified can be 
addressed by recordings from slice preparations.  Dendritic D2 receptors present in the VTA 
and SNc, and are activated by somatodentric dopamine release (Beart et al., 1979; Cheramy 
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et al., 1981).  Somatodendritic D2 receptor function can be evaluated by whole-cell 
recordings of dopamine-mediated inhibitory postsynaptic currents from midbrain slices.  
Dopamine release is also regulated by presynaptic D2 autoreceptors in the terminal fields of 
the striatum and NAc (Starke et al., 1989; Wolf and Roth, 1990).  Presynaptic D2 receptor 
function can be isolated from somatodendritic D2 receptors, in striatal coronal slices 
containing denervated dopamine terminals.  It is then possible to electrically stimulate the 
axon fibers and use FSCV to measure dopamine release following D2 agonist/antagonist bath 
application.  FSCV recordings from denervated slices may also help clarify whether the 
changes in dopamine release in AS are cell autonomous, circuit-dependent or a combination 
of the two.   
5.2.2. Ube3a substrate α-synuclein 
α-Synuclein was identified as a tentative Ube3a substrate in culture, but changes in α-
synuclein protein levels have yet to be verified in the AS mouse model (Mulherkar et al., 
2009).  The endogenous role of α-synuclein is unknown, but aggregation of the protein has 
been implicated in dopaminergic neurodegeneration and the pathogenesis of Parkinson’s 
disease (Lee and Lee, 2002; Recchia et al., 2004).  It is hypothesized that α-synuclein may 
help maintain homeostasis of dopamine metabolism, and that diseases such as Parkinson’s 
are caused by disruption of this homeostasis (Yu et al., 2005).  α-Synuclein affects several 
processes involved in dopamine metabolism; 1) regulates dopamine biosynthesis by 
inhibiting TH activity (Perez et al., 2002), 2) inhibits DAT trafficking to the plasma 
membrane (Wersinger et al., 2003; Wersinger et al., 2004), 3) disrupted vesicular recycling 
(Nemani et al., 2010).  If α-synuclein is a Ube3a substrate, I would predict elevated levels of 
α-synuclein in AS, resulting in a reduction of dopamine and membrane bound DAT.  
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However, when I took frozen tissue punches from the dorsal striatum and NAc and analyzed 
them with high-performance liquid chromatography there was no detectable difference in 
dopamine content in AS mice.  There was also no evidence of reduced membrane-bound 
DAT, when functionally assessed by FSCV.  Elevated α-synuclein levels have been shown to 
inhibit dopamine release by disrupting vesicle reclustering following endocytosis (Nemani et 
al., 2010).  Coincidentally, reductions in vesicular availability have also been observed at 
inhibitory and excitatory synapses in the cortex of AS mice (Wallace et al., 2012).  Deficits 
in the reclustering of vesicles are observed with modest overexpression of α-synuclein that 
precedes degeneration, and could account for the decrease in striatal dopamine release seen 
in AS mice.   
5.2.3. GABAergic inhibition of dopamine neurons 
Reduced inhibitory drive has been described in the visual cortex and the cerebellum 
of AS mice, however little is known about inhibitory function in the basal ganglia of AS 
(Cheron et al., 2005; Egawa et al., 2012; Wallace et al., 2012).  Considering the anatomical 
and functional connections between dopamine and GABAergic systems in the mesolimbic 
and nigrostriatal pathways, it seems likely that inhibitory dysfunction in the basal ganglion 
would directly influence dopamine neurotransmission.  Both active and spontaneous 
dopamine release is modulated by local GABAergic interneurons in the VTA and SNc 
(Kosaka et al., 1987; Hajos and Greenfield, 1994; Westerink et al., 1996).  Dopamine release 
is also inhibited by descending GABAergic projections from the striatal complex, composed 
of the NAc, striatum, ventral pallidum and globus pallidus (Smith and Bolam, 1990).  A 
reduction in inhibition would be expected to increase dopaminergic transmission  
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5.2.4. Ube3a reinstatement in dopamine neurons 
Dopamine neurons play an important role in various brain functions including 
motivation, reinforcement learning, and motor control.  The dopaminergic activity that 
guides these behaviors is modulated by synaptic projections from dozens of brain regions 
throughout the neocortex, thalamus, basal ganglia, midbrain and hindbrain (Watabe-Uchida 
et al., 2012).  The heavy modulation of dopamine activity makes it more difficult to 
determine what changes in dopaminergic function, due to loss of Ube3a expression, are 
because of cell autonomous changes rather than alterations in other ascending circuits.  One 
strategy already talked about, is severing synaptic inputs in brain slices, but this does not 
preclude developmental influences from other afflicted brain regions.  A more novel 
approach is restricted reinstatement of Ube3a in dopamine neurons, made possible by the 
Cre/loxP gene expression system.  This can be accomplished by using an established CRE 
line under the TH promotor, and a novel genetic tool that allows for CRE-dependent 
reinstatement of Ube3a (TH-Cre;lox-Stop-lox-Ube3a).  An AS mouse model with 
dopaminergic Ube3a expression would be invaluable in parsing out which AS deficits are 
specifically due to dopamine neurons.  Determining the contribution of dopaminergic 
dysfunction to AS is important in better understanding the value of dopamine replacement 
therapy.   
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